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Abstract 
 
The Effects of 7,8-Dihydroxyflavone (7,8-DHF) on Hippocampal Neurogenesis Following 
Traumatic Brain Injury 
 
By 
Mary Wurzelmann 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University 
 
Virginia Commonwealth University 2016 
 
Advisor: Dong Sun, MD, PhD, Department of Neurosurgery 
 
 
Following traumatic brain injury (TBI), the hippocampus is particularly vulnerable to 
damage, and BDNF, an endogenous neurotrophin that activates the TrkB receptor, has been 
shown to play a key role in the brain’s neuroprotective response. Activation of the TrkB 
signaling pathway by BDNF in the CNS promotes cell survival and aids in cell growth. 
However, due to its inability to cross the blood brain barrier (BBB), the therapeutic advantages 
of BDNF treatment following TBI are limited. 7,8-Dihydroxyflavone (7,8-DHF) is a flavonoid 
that mimics the effects of BDNF, is a potent TrkB receptor agonist, and can successfully cross 
the BBB. Our lab has previously demonstrated that administration of 7,8-DHF post-TBI results 
in improved cognitive functional recovery, increased neuronal survival, and reduced lesion 
volume.  
The current study examined the effects of 7,8-DHF on neurogenesis and neuronal 
migration in the dentate gyrus following TBI. In this study, adult male Sprague-Dawley rats were 
subjected to moderate controlled cortical impact injury (CCI) or sham surgery. Injured animals 
received 5 daily single doses of 7,8-DHF treatment (i.p) or vehicle starting either 60 mins after 
injury or 2 days after injury. BrdU was administered in 3 doses at 2 days post-injury for animals 
sacrificed at day 15, and single daily doses at days 1-7 post-injury for animals sacrificed at day 
28 to label cell proliferation. Animals were sacrificed at 15 days or 28 days post-injury to 
examine cell proliferation, generation of new neurons, and differentiation of newly generated 
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cells using proliferation marker Ki67, immature neuronal marker DCX, and BrdU double-
labeling with markers for mature neurons (NeuN), astrocytes (GFAP) and microglia (Iba1).    
We found that administration of 5 doses (5mg/kg) of 7,8-DHF beginning two days post-
injury had the strongest effect on neurogenesis and migration, but did not have a significant 
prolonged effect on cell proliferation at 15 days post-injury. We also found that 7,8-DHF 
treatment given early or 2 days post-TBI did not affect the neuronal differentiation in the granule 
cell layer. However, a higher percentage of BrdU/GFAP+ and BrdU/IBa1+ cells were found in 
the hilus regions in 7,8-DHF treated animals, suggesting newly generated cells in this region are 
mostly glial cell types. Our results suggest that 7,8-DHF has neurotrophic-like therapeutic effects 
following injury, and due to increased neurogenesis (compared to injured animals treated with 
vehicle), may effectively contribute to greater cell survival long-term. Additionally, potential 
long-term survival coupled with increased outward migration from the subgranular zone may 
result in increased integration of newly formed neurons into existing hippocampal circuitry, 
further contributing to cognitive recovery. 
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Chapter 1: Introduction 
 
1.1 Definition and Epidemiology of Traumatic Brain Injury 
Traumatic Brain Injury (TBI) is the loss or alteration of brain function generated by an 
external force (Menon et al., 2010).  TBI can be diagnosed with symptoms and signs that are 
temporally close to the external insult, including damage to blood vessels, axons, neurons, and 
glia, which are considered primary damages. However, it is critical to recognize delayed 
manifestations of injury, which can arise as complications of primary injury, and include 
hypoxia, ischemia, edema, and central nervous system (CNS) infection, among others (Menon et 
al., 2010; Tsao et al., 2010). Neuronal cell death following TBI can also be categorized into 
primary and secondary injury, where primary refers to the immediate death of cells on impact 
from the external disruption and secondary refers to delayed cell death as a result of 
physiological and biochemical changes in the surrounding area as a result of the injury (Stoica 
and Faden, 2010).  
Traumatic Brain Injury is a global public health issue with few treatment options 
available (Chauhan, 2014). With approximately 10 million people affected by TBI annually, it is 
a major cause of death and disability worldwide, and the World Health Organization projects that 
it will surpass the mortality and morbidity of many diseases by the year 2020. Low and middle-
income families, as well as developing countries bear the greatest burdens of TBI, as they may 
not possess the financial means or access to adequate health systems to properly handle its 
outcomes.  It is difficult to quantify the full magnitude of TBI, as multiple factors influence it 
being underreported, including mild head trauma, which is the most common brain injury, not 
being reported, its “silent” effects, which may not be physically observed, but present in the form 
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of memory or cognitive deficits, and the fact that it is commonly mislabeled as a different cause 
of death or injury in statistics (Hyder et al., 2007). 
According to the CDC, children aged 0-4 and 15-19 experience the highest rates of TBI, 
with adults over the age of 75 trailing close behind (Laskowitz and Grant, 2015). For young 
people, athletes, and members of the military, the risk of recurrent head trauma, especially mild 
TBI, presents an additional concern, as this may increase the risk of cognitive deficits or 
neurodegenerative disorders later in life (Guskiewicz et al., 2005). In addition to the long-term 
physical impairments caused by TBI, which 80,000-90,000 Americans experience annually, the 
economic cost of TBI, which can present in the form of missed work, hospital bills, and lost 
productivity, exceed $60 billion annually (Thurman et al., 1999; CDC Injury Fact Book, 2006). 
1.2 Traumatic Brain Injury Model: Controlled Cortical Impact (CCI) Injury 
To gain a better understanding of the clinical outcomes and potential treatment options 
following TBI, several injury models have been created. The two most commonly used TBI 
models are controlled cortical impact (CCI) injury and fluid percussion injury (FPI), the former 
of which will be used in this study. These models have been shown to produce motor and 
cognitive impairments which resemble those seen in TBI patients (Yu et al., 2009). It has been 
demonstrated that mild TBI from the CCI model causes profound neuronal apoptosis in the 
anterior thalamus and cortex, as well as significant axonal injury in subcortical white matter 
tracts (Dikranian et al., 2008). Furthermore, activation of Microglia, which comprise the innate 
immune system of the CNS, has been shown to be significantly upregulated in the hippocampus 
immediately following CCI injury, contributing to a pronounced inflammatory response and 
exacerbating neural damage. The highest levels of microglial activation have been observed at 3 
days post injury (Sandhir et al., 2008).  
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1.3 Pathophysiology Following TBI 
Primary cell injury is the damage that occurs immediately following injury. In the 
moments following impact, there is a significant release of a variety of neurotransmitters that is 
associated with the mechanical disturbance of neurons. Within the large release of 
neurotransmitters are glutamate and other excitatory neurotransmitters, which causes an influx of 
extracellular calcium into the cell. This, in turn, leads to the release of intracellular calcium 
stores, and results in high intracellular calcium levels that are sufficient to cause cytotoxic injury 
and cell death. The mechanical disruption of the axolemma and neuronal cell membrane also 
causes an influx of extracellular calcium and has the same aforementioned effects. The temporal 
length and degree of distortion, however, determine the fate of the membranes, as cells that are 
not severely damaged may be able to repair and reseal, while severely damaged cells may fall 
into an increasingly disrupted state or cell death (McAllister, 2011). 
High levels of intracellular calcium activate caspases and calpains, and also produce free 
radicals, which disrupt cytoskeletal elements (McAllister, 2011; Farkas and Povlishock, 2007). 
Caspases require energy to activate apoptotic pathways slowly over hours and weeks. Calpains 
rapidly activate the necrosis pathway in an energy-independent manner and trigger an 
inflammatory response. The activation of this pathway is thought to be related to energy failure, 
and the collapse of cellular homeostasis that ensues. Calpains are proteases whose primary 
substrates include neurofilaments and spectrins, which, when acted upon by calpains, disrupt cell 
transport and destroy cytoarchitecture, ultimately leading to cell death (Farkas and Povlishock, 
2007; Friedlander, 2003; Raghupathi, 2004). 
Beyond the intracellular events caused by the disruption of calcium homeostasis and the 
release of free radicals, the rupturing of lysosomal membranes caused by the mechanical force of 
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the injury results in intracellular release of hydrolytic enzymes (Farkas and Povlishock, 2007). In 
addition to the significant release of glutamate described above, the excessive release of 
acetylcholine may exacerbate the negative effects of excitatory amino acids, which are also 
present in excess following injury. This can have especially harmful effects in the hippocampus 
and frontal cortices, where excitatory amino acids and acetylcholine are colocalized in high 
concentrations (Phillips and Reeves, 2001).  
1.3.1 Neuronal death following TBI 
While neuronal cell death is a normal part of CNS development, as a process to remove 
dysfunctional cells, it can have detrimental cognitive effects and result in neurodegenerative 
disorders if it occurs in excess, as it does in TBI. Caspases, or cysteine-dependent aspartate-
specific proteases, are a family of proteases responsible for mediating various components of 
apoptosis, or programmed cell death. Necrosis (passive cell death) and apoptosis are associated 
with caspase-1 and caspase-3, respectively (Eldadah and Faden, 2000). In lateral Fluid 
Percussion Injury (FPI) and Controlled Cortical Impact (CCI) injury models in rats, and also 
demonstrated in humans, there is an increase of caspase-1 and caspase-3 activity in the cortex 
and hippocampus following TBI (Yakolev et al., 1997; Clark et al., 2000; Clark et al., 1999), 
which is consistent with an increase in cell death in those regions (Basil and Faden, 2000). 
Neurodegeneration after TBI can have adverse effects in many regions of the brain, leading to 
deficits in cognition, motor function, and psychological function, but the hippocampus is 
considered one of the most vulnerable regions to injury, as damage to this region can result in 
memory and learning deficits (Chauhan, 2014; Smith et al., 1991).  
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1.3.2 Neurogenesis Following Traumatic Brain Injury 
Adult neurogenesis is the process of generating new cells in a mature brain, and it is 
known to take place in the subgranular zone (SGZ) of the dentate gyrus (DG) and subventricular 
zone (SVZ) of the lateral ventricles in the mammalian CNS. Although many cells, particularly 
progenitor stem cells, are more susceptible to apoptosis during neurogenesis, BDNF synthesis 
during this period promotes the viability of new neurons (Gomazkov, 2012). Progenitor cells 
from the SGZ migrate to the granular cell layer (GCL) and differentiate into mature granular 
neurons. This migration is normally guided by radial glial fibers during development, and is 
likely guided by these same fibers in the mature brain, as their presence persists in adulthood 
(Kornack and Rakic, 1999).  
It has been demonstrated in multiple studies that TBI (either fluid percussion injury or 
controlled cortical impact) leads to an endogenous increase in stem cell proliferation in the 
hippocampus (Sun et al., 2005; Chirumamilla et al., 2004; Dash et al., 2001). Neural stem cell-
supported adult neurogenesis may provide a compensation method for neuronal loss following 
TBI (Wang et al., 2015). In a FPI model, both juvenile and adult rats demonstrated robust 
neuronal proliferation of the ipsilateral dentate gyrus, specifically in the SGZ and hilus.  The 
proliferative response was strongest at 48 hours post-injury, and continued for 7 days in the SGZ, 
but ultimately declined by day 14 to the same levels as sham animals, as shown in Figure 1.1 
(Sun et al., 2005).  
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Figure 1.1: Cell Proliferation in the Ipsilateral Dentate Gyrus following Fluid Percussion 
Injury. Graphs demonstrate significantly increased cell proliferation at 2 and 7 days post-injury 
in the SGZ, and at 2 days post-injury in the hilus (Sun et al., 2005). 
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It has been established that adult neurogenesis in the hippocampus, specifically adult-
born granule cells of the dentate gyrus, plays an important role in hippocampal dependent 
learning and memory function (Deng et al., 2009; Clelland et al., 2009). Our lab and others have 
also demonstrated that TBI enhances hippocampal neurogenesis, and newly generated neurons 
are able to successfully integrate into existing hippocampal circuitry (Emery et al., 2005; Sun et 
al., 2007). The successful integration of new neurons into surrounding circuitry coincides with 
the time of innate cognitive recovery, suggesting a link between post-TBI hippocampal 
neurogenesis and cognitive recovery (Sun et al., 2007). Furthermore, studies that augment post-
TBI hippocampal neurogenesis with growth factors, such as epidermal growth factor and basic 
fibroblast growth factor, have shown improved cognitive functional recovery (Sun et al., 2009; 
Sun et al., 2010). These studies suggest that manipulation of the brain’s endogenous cell 
response may provide a unique opportunity for brain regeneration following TBI. 
However, severity of injury has been shown to affect adult neurogenesis of the 
hippocampus. Moderate TBI has been shown to promote neural stem cell (NSC) proliferation, 
but not affect neurogenesis, while severe TBI increased the three stages of neurogenesis: 
proliferation, migration, and differentiation, in the hippocampal dentate gyrus (Wang et al., 
2015).  
1.4 Neurotrophins 
Neurotrophins are endogenous peptides secreted from neuronal and glial cells, and are 
associated with regulating the function, survival, and development of individual cells and 
neuronal networks across the entire brain. More specifically, neurotrophins regulate synaptic 
plasticity, protect neurons from oxidative stress and apoptosis, and can aid in the replacement of 
damaged neurons by stimulating progenitor stem cells, which leads to neurogenesis. The 
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neurotrophin family of growth factors includes Nerve Growth Factor (NGF), Brain-derived 
Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), and Neurotrophin-4/5 (NT-4/5), which are 
classified together based on their structural similarity to NGF, the first neurotrophin discovered. 
Although neurotrophins are present in multiple structures across the brain, they have the highest 
level of expression in the hippocampus, particularly NGF, NT-3, and BDNF, with BDNF 
showing the greatest level of expression following an initial development period with high NT-3 
expression. Within the hippocampus, activated glutamate receptors stimulate the production of 
neurotrophins during changing environmental conditions in the brain (Gomazkov, 2012). 
Due to their role in regulating neuronal survival, function, and development, 
neurotrophins provide valuable protective and repair functions that attenuate neuronal damage. 
Neuroprotective functions of neurotrophins range from cytoskeleton stabilization, suppressed 
amyloid deposition, and balancing neurotransmitter levels, to preventing neurodegeneration and 
promoting neurogenesis (Gomazkov, 2012). Neurotrophins have also been implicated in multiple 
neurodegenerative disorders and pathophysiological states, as defects in their expression can 
contribute to diseases, such as Alzheimer’s Disease and Parkinson’s Disease (Price et al., 2007; 
Gomazkov, 2012). Early, preclinical stages of dementia are often accompanied with lower than 
normal levels of NGF in the frontal cortex, but as the disease progresses, there is a compensatory 
increase in NGF. This pattern of disrupted NGF regulation is characteristic of a variety of 
diseases, ranging from Alzheimer’s Disease to diabetic neuropathy (Gomazkov, 2012; Shaub et 
al., 2014; Siegel and Chauhan, 2000). 
Neurotrophins are able to exert their neuroprotective effects through the transmembrane 
receptors they bind to and the signaling cascades they initiate. There are two main classes of 
transmembrane neurotrophin receptors, which include tropomyosin-related kinase (Trk) family 
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of tyrosine kinase receptors, TrkA, TrkB, and TrkC, and the p75 Neurotrophin receptor (p75NTR), 
a member of the tumor necrosis-factor family (Marco-Salazar et al., 2014). NGF preferentially 
binds to TrkA, BDNF and NT-4/5 to TrkB, and NT-3 to TrkC, all with high affinity, while each 
of these neurotrophins binds with low affinity to p75NTR receptors (Gomazkov, 2012; Marco-
Salazar et al., 2014). Additionally, p75NTR contributes to proper Trk receptor function, and 
promotes ligand binding of neurotrophins with their correct Trk receptor (Skaper, 2012). Once 
bound to their Trk receptors, neurotrophins activate a cascade of events through Ras, 
phosphatidylinositol 3-kinase(PI3K), phospholipase-Cɣ (PLCɣ), and mitogen-activated protein 
kinase (MAPK) signaling pathways (Skaper, 2012). 
1.4.1 Neurotrophins in Response to Traumatic Brain Injury 
By virtue of their role in neuronal growth, differentiation and replenishment, it is no 
surprise that neurotrophins play a physiologically important role in protecting the brain following 
TBI (Gomazkov, 2012). Neurotrophic therapy first became a concept following the discovery of 
NGF’s ability to induce neuronal survival and repair after injury (Cohen et al., 1954; Levi-
Montalcini, 1987). This led to studies investigating the presence of additional growth factors 
following brain injury or insult and the potential therapeutic uses of neurotrophins for TBI and in 
neurodegenerative diseases, such as Parkinson’s Disease (Gomazkov, 2012). 
Immediately following TBI, mRNA expression of NGF and BDNF is transiently and 
significantly increased. As early as 12 hours post-injury, levels of BDNF and NGF mRNA are 
significantly upregulated at the site of injury and in remote regions of the brain (non-injury sites), 
but levels of BDNF begin to decline at 24 hours post-injury, and are no longer significantly 
elevated at 36 hours post-injury in both regions. NGF mRNA levels, conversely, are significantly 
elevated at 12 hours post-injury, increase at 24 hours post-injury, and begin to decline at 36 
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hours post-injury, at which point their levels are three-times that of controls, but not statistically 
significant in both regions. These results demonstrate that although BDNF reacts faster following 
TBI, its response ends sooner than the response of NGF (Oyesiku, 1999). In addition to an 
upregulation of neurotrophins at the site of injury and in remote areas, TrkB receptors, which 
bind BDNF, are also transiently upregulated in the hippocampus and dentate gyrus following 
neural insults (Merlio et al., 1993).  
1.4.2 Brain-derived Neurotrophic Factor (BDNF) and its receptors 
Brain-derived Neurotrophic Factor (BDNF) is a neurotrophin that is produced in the 
endoplasmic reticulum (ER) as a precursor protein, known as prepro-BDNF, transferred to the 
Golgi apparatus for further processing where it becomes pro-BDNF, and finally is placed as 
mature BDNF in secretory vesicles, from which it can be released at the presynaptic terminal via 
an active calcium-dependent manner (Gomazkov, 2012). Pro-BDNF is secreted in an activity-
dependent manner, and is cleaved by enzyme tissue plasminogen activator to produce mature 
BDNF (Waterhouse and Baoji, 2009). BDNF is known to activate intracellular signaling 
pathways through both TrkB and p75NTR receptors (Gomazkov, 2012). Additional studies have 
shown that pro-BDNF primarily acts through binding the lower affinity p75NTR receptor, while 
mature BDNF acts through the higher-affinity TrkB receptor (Roux and Barker, 2002; Lessmann 
et al., 2003).  
Although it is found only at very low levels within the CNS, BDNF has been shown to 
have profound effects in regulating cell survival and other biological processes that ensure 
proper mental function (Dieni et al., 2012). BDNF signals for neurite and axonal growth (Yoshii 
and Constantine-Paton, 2010), is required for the survival and development of dopaminergic, 
GABAergic, serotonergic, and cholinergic neurons (Pillai, 2008), and is essential to learning and 
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memory, and the synaptic plasticity required by both functions (Lu et al., 2008). While BDNF 
offers great therapeutic potential because of its endogenous functions, it is limited by its poor 
pharmacokinetic profile, namely that it has a short half-life (BDNF half-life < 10 minutes), 
degrades rapidly in blood, and also diffuses poorly across the blood-brain barrier (BBB) (Price et 
al., 2007).   
 
1.4.3 BDNF-TrkB Signaling Pathway 
Upon binding to the TrkB receptor, BDNF induces dimerization and autophosphorylation 
of the receptor, which causes internalization of the TrkB receptor and initiates intracellular 
signaling cascades (Figure 1.2; Levine et al., 1998). These signaling cascades include the 
phosphatidylinositol 3 kinase (PI3K) pathway, the phospholipase C ɣ (PLCɣ) pathway, and the 
mitogen-activated protein kinase (MAPK) pathway. The PI3K pathway activates protein kinase 
B (Akt), which ultimately promotes cell survival by inhibiting Bad and consequently allowing 
the expression of anti-apoptotic proteins, such as Bcl2 (Yoshii and Constantine-Paton, 2010).  
Phosphorylation of Akt at the proper site also results in the suppression of pro-apoptotic proteins, 
pro-caspase-9 and Forkhead (Kaplan and Miller, 2000). Upregulated Bcl2 levels are correlated 
with positive outcomes, such as attenuated cell death and a better prognosis (Nathoo et al, 2004). 
The PLCɣ pathway leads to the release of intracellular calcium stores via activation of the 
inositol triphosphate (IP3) receptor, and helps to increase calmodulin kinase (CamK) activity, 
and thus synaptic plasticity via the transcription factor CREB (cyclicAMP response element 
binding protein). The MAPK pathway, also referred to as extracellular related signal kinase 
(ERK) pathway, aids in cell growth and differentiation. A PLCɣ mediated response is likely 
24 
responsible for quick, short-term actions, while MAPK and PI3K pathways involve long-term 
transcriptional effects (Yoshii and Constantine-Paton, 2010). 
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Figure 1.2: The activation pathways of the TrkB receptor. 
The MAPK pathway activation stimulates anti-apoptotic proteins, including Bcl2 and cAMP 
Response-Element Binding protein (CREB), the latter of which is required by neurotrophins for 
mediating neuronal survival. Activation of the MAPK pathway also stimulates extracellular 
signal related kinase (ERK), which is responsible for transcriptional regulation, and causes the 
phosphorylation of Synapsin I, mediating the clustering and release of synaptic vesicles. TrkB 
receptor activation also leads to the activation of the PI3K pathway, which activates Akt. Akt 
inhibits apopotosis by inhibiting the protein Bad, which, when active, inhibits anti-apoptotic 
protein, Bcl2. Pro-caspase 9 and Forkhead are pro-apoptotic proteins that are suppressed when 
Akt is phosphorylated at the apoptosis protein on the Akt consensus phosphorylation site. (PI3K 
= phosphatidylinositol 3 kinase; Akt = Protein Kinase B, PKB; Bad = Bcl2 associated death 
promoter) PI3K does not interact directly with Trk receptors. However, adaptor proteins such as 
GRB-associated binder-1 (GAB1), insulin-receptor substrate 1 (IRS1) and IRS2, which are 
recruited to activated TrkB through GRB2 binding, mediate the association and activation of 
PI3K with TrkB. Finally, the Phospholipase C-gamma (PLC ϒ) pathway is also activated by the 
TrkB receptor. PLC-gamma can lead to an increase in intracellular calcium levels, which 
activates the calcium/calmodulin pathway, which can then activate CREB.  
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1.4.4 BDNF-TrkB Receptor Signaling and Neurogenesis 
Data suggests that neurotrophins play a crucial role in neurogenesis in the CNS 
(Gomazkov, 2012). An increase in BDNF alone will not result in neurogenesis, as presence of its 
TrkB receptor is necessary for the proper organization and growth of dendrites and spines, as 
well as neurogenesis-dependent long-term potentiation (LTP), which is essential for memory 
processes (Bergami et al., 2008; Cooke and Bliss, 2006). Neurogenesis is critical to normal brain 
and psychological functions, and the lack of TrkB signaling, and thus neurogenesis, has 
implications in mood-related behavior, specifically increased anxiety. This underscores the 
importance of neurogenesis and neurotrophins restoring proper function (Bergami et al., 2008).  
The role of BDNF in neurogenesis regulation plays out at multiple steps in the maturation 
process. While depleting central BDNF in mice increases hippocampal cell proliferation, and 
does not affect cell survival or fate, the newly proliferated cells are not able to fully mature and 
lack a neurogenic response to GABA(A) receptor stimulation (Chan et al., 2008). These studies 
indicate that without BDNF, immature neurons are not able to properly differentiate in the adult 
hippocampus. Additional studies have demonstrated that BDNF is crucial to neural stem cell 
proliferation, and when given in conjunction with a restricted diet, promotes the survival of 
newly generated neurons (Lee et al., 2002).  
Furthermore, when BDNF is administered directly to the dentate gyrus (and does not 
need to cross the BBB), there is an increase in neurogenesis of granule cells on both the 
ipsilateral and contralateral hemispheres of the hippocampus (Scharfman et al., 2005). 
Conversely, conditionally knocking-out BDNF in the hippocampal dentate gyrus causes a 
significant increase in adult-born immature neuron death after moderate TBI (Gao and Chen, 
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2009). This suggests that BDNF plays a critical role in regulating mechanisms of survival of 
immature neurons in the hippocampus, particularly following a brain insult.  
1.4.5 BDNF in Response to Traumatic Brain Injury 
Due to their valuable role in neuronal survival and proliferation, it is logical that 
neurotrophins act as an endogenous neuroprotective response following TBI, and work to 
attenuate secondary cell damage related to the pathophysiology of brain injury (Mattson and 
Scheff, 1994). Multiple studies have demonstrated that TBI modulates BDNF and TrkB mRNA 
levels bilaterally in the hippocampus. Both BDNF and TrkB mRNA levels increase bilaterally in 
the hippocampus for several hours following injury, while NT-3 mRNA expression decreases 
and TrkC, the high-affinity binding partner of NT-3, remains unchanged within the hippocampus 
(Hicks et al. 1999; Hicks et al., 1998). These alterations in neurotrophin levels are representative 
of molecular and chemical changes following TBI, and serve as early biomarkers for injury 
(Chiaretti et al., 2003).  
Rising BDNF levels in the hours and days after injury are thought to play a crucial role in 
ameliorating the effects of secondary brain injury.  Increased levels of expression have been 
found at the site of injury, in distant areas damaged by secondary mechanical stress, and areas 
connected via fiber pathways to the injured area. BDNF provides neuroprotection and works to 
restore proper connectivity following TBI, but if the injury induces chronic stress or prolonged 
glucocorticoid exposure, as in post-traumatic stress disorder (PTSD), BDNF levels can fall and 
lead to hippocampal dysfunction by causing dendritic disconnection, retraction, and rewiring 
(Kaplan et al., 2010).  
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1.5 Hippocampus following Traumatic Brain Injury 
Along with the frontal cortex and sub-frontal white matter, the hippocampus, among 
other deep midline structures, is particularly vulnerable to traumatic brain injury. Mesial 
temporal structures, which include the hippocampus and dentate gyrus, are subject not only to 
injuries from physical impact, but also cytotoxic effects from secondary injury (McAllister, 
2011). The hippocampus is of particular concern as it contains the subgranular zone (part of the 
hippocampal dentate gyrus), which is one of the two known locations in the brain to undergo 
adult neurogenesis (Gomazkov, 2012).  
Learning and memory dysfunction are common consequences of damage to the 
hippocampus. Parasagittal fluid percussion injury has been demonstrated to cause severe spatial 
memory deficits in the Morris Water Maze, a behavioral navigation task used to test spatial 
learning and memory (Smith et al., 1991). The primary and secondary insult to the hippocampus 
elicit multiple inflammatory events, which ultimately result in neuropsychiatric, cognitive, and 
motor issues. One study was able to show that although hippocampal-dependent learning and 
memory were measured as normal 7 days post-injury, at one month post-injury anterograde 
learning impairments developed. These impairments coincided with an acute immune challenge 
at 30dpi to demonstrate that microglia are still sensitized to the primary insult and overreact to 
smaller secondary insult to contribute to cognitive decline. This exhibits the fragile state of the 
hippocampus following the initial injury, and how additional cognitive deficits may develop if 
the brain has not yet fully recovered (Muccigrosso et al., 2016). 
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1.6 The Molecule 7,8-Dihydroxyflavone 
Although BDNF possesses a great deal of therapeutic potential due to its numerous 
neurological targets and key roles in neurogenesis and neuroprotection, it has a short half-life 
(<10 minutes), is cleared quickly from the circulatory system by the liver, and lacks the ability to 
cross the BBB due to its large size (27 kDa), and consequently lacks an adequate means of 
administration in a clinical setting (Baseri et al., 2012).  Because of its poor pharmacokinetic 
profile, researchers completed a cell-based drug screening to find a small molecule that can act 
as a TrkB agonist. 7,8-Dihydroxyflavone (7,8-DHF) is a flavonoid discovered in this search that 
not only specifically binds to the TrkB receptor with high affinity and induces its dimerization, 
but it also induces the receptor’s downstream signaling, is orally bioactive, and can cross the 
BBB (Liu et al., 2016). 
Flavonoids are found in fruits and vegetables, and some are known to have antioxidant 
and anti-inflammatory properties (Harborne and Williams, 2000). Other studies have shown 
positive effects of flavonoids in protecting and enhancing neural function, as well as promoting 
neuronal regeneration (Spencer, 2008). 7,8-DHF in particular mimics the effects of BDNF, and 
has been demonstrated to have positive effects in axon regeneration and a protective role in the 
pathogenesis of Alzheimer's Disease (Liu et al., 2016). Furthermore, 7,8-DHF has been shown to 
protect neurons from apoptosis; neurons that lack TrkB, the receptor for 7,8-DHF and BDNF, 
cannot be rescued from apoptosis by 7,8-DHF (Jang et al., 2010).  
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1.6.1 Pharmacokinetics of 7,8-Dihydroxyflavone 
In contrast to the short half-life of BDNF (<10 minutes), 7,8-DHF has a half-life of 134 
minutes in plasma (50 mg/kg oral administration), oral bioavailability of 5%, and can still be 
detected in the brain 4 hours after administration, despite first-pass metabolism by the liver 
(Zhang et al., 2014; Liu et al., 2016). Glucuronidation and sulfation are the two main 
modifications that result in the clearance of 7,8-DHF (Liu et al., 2016). 7,8-DHF is also 
considerably smaller than BDNF, with a molecular weight of 254 Da compared to BDNF’s 27 
kDa, which allows for greater permeability across the BBB when given orally or 
intraperitoneally (Liu et al., 2014).  
1.6.2 7,8-Dihydroxyflavone interactions with TrkB Receptor 
As stated above, 7,8-DHF binds the TrkB receptor with high affinity. Although BDNF 
has a lower dissociation constant (high binding affinity) (Kd = 1.7nm) than 7,8-DHF (Kd = 
15.4nm) with the TrkB receptor, 7,8-DHF TrkB receptor phosphorylation lasts for many hours 
longer than BDNF receptor phosphorylation. Additionally, TrkB receptors activated by 7,8-DHF 
are not degraded, but instead are recycled to the cell surface after internalization, as opposed to 
BDNF activated TrkB receptors, which are tagged for ubiquitination and degraded after 
internalization. Internalization is a vital part of initiating signal transduction for the neurotrophin-
Trk complex. 7,8-DHF can successfully mimic BDNF-TrkB internalization in neurons, 
producing endosomes with TrkB as early as 10 minutes, as BDNF does, and producing a more 
robust endocytic response than BDNF at 60 minutes (Liu et al., 2014). 
Not only does 7,8-DHF selectively promote the homodimerization of TrkB receptor and 
autophosphorylation of tyrosine residues as strongly as BDNF, it also influences its downstream 
effectors. In the downstream pathways of TrkB, binding of 7,8-DHF to the TrkB receptor 
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resulted in significant activation of Akt and ERK/MAPK pathways. In this manner, 7,8-DHF is 
able to promote the same neuroprotective effects as BDNF (Jang et al., 2010).  
1.6.3 Current Experimental Findings of 7,8-DHF in the Treatment of TBI: Behavioral 
Level Response 
Since its discovery, 7,8-DHF has been documented in providing neuroprotection and 
neuroplasticity in various neurological diseases and disorders (Liu et. al., 2012). Unlike BDNF, 
7,8-DHF has a much longer half-life and can easily pass the blood-brain barrier, making it a 
possible alternative in treating TBI (Zeng et. al., 2012; Wu et. al., 2014). In mouse models 
employing controlled cortical impact (CCI) injury, there was significant improvement in 
neurological function at days 14, 21, and 28 post-injury in mice given 7,8-DHF (20mg/kg) at 
four days after CCI compared to the control group (Wu et al., 2014).  
This was demonstrated in rotarod and beam-walking tests, which test motor and 
coordination function, and resulted in 7,8-DHF-treated mice performing significantly better on 
the rotarod test (not falling off or remaining on the rotarod for a longer period of time) and 
requiring significantly less time to cross in the beam-walk test as early as 7 days post-injury for 
both (Wu et al., 2014).  Additionally, rats subject to fluid percussion injury (FPI) had a 
significant increase in latency time on the Barnes maze, used to assess spatial memory and 
cognitive function, as opposed to rats treated with 7,8-DHF (5mg/kg). Latency in the Barnes 
maze test is indicative of memory impairment, suggesting that the significant reduction in 
latency time for animals treated with 7,8-DHF beginning the day of injury is due a protective 
effect 7,8-DHF offers against TBI-induced memory deficits (Agrawal et al., 2015). 
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1.6.4 Current Experimental Findings of 7,8-DHF in the Treatment of TBI: Gross Anatomic 
Level Response  
Tissue loss and brain edema are also common occurrences following brain damage that 
can be minimized with 7,8-DHF. Initial contusion volume after injury significantly decreased by 
day 28 compared to controls, and also restricted further tissue loss through atrophy, suggesting, 
again, a neuroprotective effect of 7,8-DHF. Even 4 days post-injury, when neurodegeneration 
that is normally observed at the acute stage, 7,8-DHF ameliorates neuronal damage and 
significantly decreases contusion volume (Yu et al., 2010; Wu et al., 2014). The preservation of 
brain tissue also likely contributes to long-term functional recovery (Wu et al., 2014). Brain 
edema is characterized by excess fluid and swelling (Fishman, 1975). A decrease in tissue 
volume may give way to greater brain water content. CCI induces a significant increase in water 
content of the affected/ipsilateral hemisphere compared to the contralateral hemisphere, an effect 
that is significantly lessened by the treatment of 7,8-DHF given 4 days post-injury (Wu et al., 
2014). 
Tissue preservation by 7,8-DHF after brain injury also reflects a decrease in cell 
apoptosis. Cleaved caspase-3 is a main effector of the apoptotic cascade (Gown and Willingham, 
2002), and by 4 days post-injury its levels in 7,8-DHF-treated brains had significantly decreased 
compared to controls (Wu et al., 2014). Additionally, the ratio between anti-apoptotic and pro-
apoptotic Bcl-2 proteins increases with 7,8-DHF, implying that its protective effects include 
preventing apoptosis after injury (Wu et al., 2014).  
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1.6.5 Current Experimental Findings of 7,8-DHF in the Treatment of TBI: Metabolic 
Response 
Mitochondrial biogenesis is the growth and division of preexisting mitochondria, and 
requires the co-transcription factor PGC-1α (peroxisome-proliferator-activated receptor γ co-
activator-1α) to activate several other transcription factors which will activate mitochondrial 
transcription factor A (TFAM) and induce mitochondrial biogenesis.  PGC-1α is important in 
linking the internal metabolic response to external stimuli (Jornayvaz and Shulman, 2010). TBI 
negatively affects PGC-1α levels in the brain, and corresponds with increased latency times in 
the Barnes maze test, suggesting its absence may contribute to poor memory function. PGC-1α 
levels and a lower latency time are restored when injured animals are given 7,8-DHF (Agrawal et 
al., 2015).  
In addition to the restoration of PGC-1α levels, 7,8-DHF also lessens the impact of TBI 
on TFAM protein, cytochrome oxidase, and SIRT2 protein levels through activation of the TrkB 
receptor (Agrawal et al., 2015). TFAM is the final component driving transcription and 
replication of mitochondrial DNA, so it would follow that appropriate levels of TFAM would 
allow for proper mitochondrial biogenesis following environmental stress, including cell division 
and renewal and oxidative stress that result from TBI (Jornayvaz and Shulman; 2010). 
Mitchondrial cytochrome oxidase II (COII), which is important in mitochondrial oxidative 
phosphorylation, and serves as an indicator of the mitochondrial function to mass ratio, also has 
reduced levels following brain injury. The enzyme’s levels are maintained after injury, however, 
if 7,8-DHF is given the day of injury. As shown with reduced levels of PGC-1α, lower levels of 
COII are also reflected in an increased latency time in the Barnes maze test, suggesting that 
memory function may rely on the function and levels of mitochondrial proteins (Agrawal et al. 
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2015). Sirtuin 1 (SIRT2) protein is induced during fasting, and activates PGC-1α via 
deacetylation. Deficits in SIRT2 would result in an inability to respond to urgent metabolic needs 
that result from sensing energy deficits during fasting (Jornayvaz and Shulman; 2010). Like 
TFAM and COII levels, SIRT2 protein levels were restored with the treatment of 7,8-DHF 
(Agrawal et al., 2015). 
Cellular energy levels are closely monitored by AMP activated protein kinase (AMPK), 
which is an important regulator of mitochondrial biogenesis. Mitochondrial biogenesis, in turn, 
activates the metabolic response to cellular energy crises (Jornayvaz and Shulman; 2010). 
Following TBI, AMPK phosphorylation decreases, reducing or inhibiting the transcription of 
mitochondrial DNA. 7,8-DHF treatment significantly raises the levels of AMPK phosphorylation 
after TBI, and also increases AMPK levels in sham animals. Presumably this response will aid in 
meeting the energy demands of neuronal growth following injury (Agrawal et al. 2015).  
Cognitive and emotional disturbances are coupled with brain damage, as well, and often 
present in the form of depression and anxiety (Cohen et al., 2007; Signoretti et al., 2010; Pandey 
et al., 2009). These disorders have been linked to metabolic disturbances, which may underscore 
the importance of 7,8-DHF restoring PGC-1α, COII, and SIRT2 to homeostatic levels (Vagnozzi 
et al., 2010; Agrawal et al., 2015). BDNF has been shown to participate in glucose utilization 
and energy management (Yamanaka et al., 2007), so it follows that using the TrkB agonist 7,8-
DHF to stimulate the pathway should restore metabolic functions to homeostatic levels and 
relieve the cognitive and behavioral disturbances associated with its imbalance (Agrawal et al., 
2013; Zhang et al, 2015). After 8-12 hours of 7,8-DHF treatment (200nM), neuro-2a (N2a) cells 
show increased cellular respiration, as measured by a higher oxygen consumption rate (OCR), 
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suggesting that the activation of this pathway increases the mitochondrial reserve capacity of 
cells, improving mitochondrial function (Agrawal et al., 2013).  
1.6.6 Current Experimental Findings of 7,8-DHF in the Treatment of TBI: Molecular Level 
Response 
The presence of 7,8-DHF also has quantitative effects on a molecular level. Under 
normal conditions, the binding of neurotrophins to Trk receptors induces the phosphorylation of 
tyrosine residues on the intracellular domain, specifically TrkB Tyr515, Tyr706, and Tyr816. 7,8-
DHF also induced phosphorylation of the same residues, but elicited weaker signals than BDNF 
(Xia et al; 2014). Sham animals not subject to TBI, however, had a significant increase in TrkB 
phosphorylation when treated with 7,8-DHF. Animals subject to FPI had a significant reduction 
in the phosphorylation of TrkB, which was reversed with the treatment of 7,8-DHF, suggesting a 
potential therapeutic use of the flavonoid (Agrawal et al; 2015). Downstream signaling pathways 
of TrkB, such as PI3K/Akt pathways, were also restored when TBI was followed with 7,8-DHF, 
increasing Akt Ser473 phosphorylation by as much as 198% compared to vehicle treatments. The 
phosphorylation of TrkB receptors following TBI has been analyzed further within the 
hippocampus, and has shown a qualitative decrease in phosphorylation, particularly within the 
CA3 region. This molecular-level phenotype corresponded with the observation that TrkB 
phosphorylation is inversely related to latency time in the Barnes maze, suggesting a link 
between memory performance and the TrkB signaling pathway (Agrawal et al; 2015).  
Blocking TrkB phosphorylation with K252a, a TrkB antagonist, prevents the beneficial 
cognitive, motor, and cellular effects observed with 7,8-DHF administration following brain 
injury. Injecting K252a into the hippocampus counteracts memory improvement demonstrated in 
the Barnes maze test, and reduces TrkB phosphorylation, CREB phosphorylation, and PGC-1α 
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levels in animals treated with 7,8-DHF (Agrawal et al., 2015).  Additionally, K252a completely 
reverses the reduction in contusion volume induced by 7,8-DHF. This has been replicated using 
the PI3K inhibitor LY294002, which also abolishes the protective effect of 7,8-DHF, leading to 
an increased injury volume compared to the animals treated with only 7,8-DHF (Wu et al., 
2014). 
In addition to an increase in phosphorylation of TrkB and its downstream targets, which 
results in activation of several proteins leading to the mediation of neuronal survival and vesicle 
release (Kaplan & Miller, 2000; Wang et. al., 2010; Waterhouse & Xu, 2009), 7,8-DHF also 
induces an increase in CREB phosphorylation level at day 4 post-injury. Phosphorylated CREB 
is a key transcription factor for the production of BDNF, and consequently, as levels of CREB 
phosphorylation increase, so do levels of BDNF. This indicates that the endogenous increase of 
BDNF likely contributes to 7,8-DHF’s protective effects via a positive feedback loop (Wu et al; 
2014). In the neocortex, BDNF has been shown to play a critical role in fear memory and 
learning, and when treated with 7,8-DHF, memory and learning deficits induced by low levels of 
BDNF are rescued (Choi et al; 2009). 
In addition phosphorylating key components of the TrkB pathway, 7,8-DHF also restores 
GAP-43 and syntaxin-3 levels. GAP-43 is a protein associated with axonal regeneration, serves 
as a growth and plasticity indicator, and is highly expressed during development (Benowitz and 
Routtenberg; 1997). Syntaxin-3 is a protein charged with transporting vesicles for exocytosis and 
assisting with the growth of neuritis (Martín-Martín et al., 1999). Restoration of both of these 
proteins’ levels has important implications for the reestablishment of brain plasticity and 
recovery following injury. Differences in these proteins’ activity following treatment with 
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vehicle versus 7,8-DHF are also qualitatively different in subregions of the hippocampus 
(Agrawal et al. 2015).  
1.7 Summary and Hypothesis 
Traumatic brain injury is a serious medical issue worldwide. Primary and secondary 
damages caused by TBI have long-lasting effects due to the activation of calpains and caspases, 
as well as inflammatory responses, which can lead to overactivation of microglia, ultimately 
leading to neurodegeneration (Wood, 2002). 
This study seeks to elucidate the therapeutic potential for 7,8-Dihydroxyflavone in the 
context of neurogenesis following traumatic brain injury. Based on previous unpublished data, 
we have found that 7,8-DHF has neuroprotective and neural plasticity effects in the injured brain, 
and that post-TBI treatment can improve cognitive functional recovery, reduce lesion volume, 
and increase neuronal survival. In this study, we will explore the neurogenic effect of 7,8-DHF 
following TBI by examining levels of cell proliferation, generation of new neurons, and cell type 
differentiation in two treatment groups. 
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Chapter 2: Methods 
2.1 Experimental Animals 
Male Sprague-Dawley rats (300-350g) aged 3 months old were used in this experiment. 
Rats were housed in pairs in the Division of Animal Resource (DAR) facilities at a temperature 
between 20-22  on a 12-hour light/dark cycle, and fed ad libitum. Animals acclimated to this 
environment for one week prior to beginning behavioral testing and surgery. A total of 32 
animals were included in this study. Animals were randomly divided into two sets: Day 15(D15) 
animals (n=20), which were sacrificed 15 days post-injury, and Day 28 (D28) animals (n=12), 
which were sacrificed 28 days post-injury. Within each experimental group, D15 and D28, 
animals were randomly assigned to a treatment group (Table 2.1). The D15 group was comprised 
of 4 treatment groups, including sham animals (n = 3), animals which received CCI and vehicle 
treatment (n = 7), animals which received CCI and 7,8-DHF beginning the same day as injury 
(DHF Group 1; n = 5), and animals which received CCI and 7,8-DHF beginning two days post-
injury (DHF Group 2; n = 5). The D28 animals were divided into 4 treatment groups, which were 
the same as the D15 experimental group. Animals were sacrificed at D15 to examine survival 
and migration, and at D28 to examine differentiation and survival of new neurons in the 
hippocampus.  
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Animal Treatment Groups 
Sacrificed Sham CCI + Vehicle CCI + DHF Group 1 CCI + DHF Group 2  Total 
D15 3 7 5 5 20 
D28 1 4 4 3 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
 
 
 
 
 
 
 
 
 
Table 2.1 Animal Treatment Groups for Day 15 (D15) and Day 28 (D28) Animals in 7,8-
Dihydroxyflavone Study; Comparing post-injury endogenous neurogenesis response to post-
injury neurogenesis with 7,8-DHF administration. 
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2.2 Controlled Cortical Impact (CCI) Injury 
A total of 28 (+4 sham) animals received controlled cortical impact (CCI) injury for this 
experiment using a Benchmark Stereotaxic Impactor. The animals were sedated with 2.5% 
isofluorane (in 30% O2 and 70% N2), and remained under sedation for the duration of the 
procedure. A paw-pinch reflex was tested every 10-15 minutes throughout the procedure to 
ensure continued sedation. Once sedated, the top of the animal’s head was shaved where the 
incision to open the scalp would be made. The rats were then placed in a stereotactic frame 
attached to the impactor, where their head was held in place by ear bars and a biting plate, which 
their jaw was attached to. To prevent their eyes from drying out, an ophthalmic lubricant 
ointment was applied to both eyes once the animal was set in the stereotactic frame. To reduce 
the possibility of infection, betadine, an iodine antiseptic, was applied along the scalp where the 
incision would be made. Rats were placed on thermostatically controlled heating pad to maintain 
a stable body temperature. 
The incision was made along the midline of the scalp with a sterile scalpel blade. Skin 
and fascia were held apart with hemostats on either side of the head to keep the skull exposed 
throughout the procedure. To gain access to the brain tissue, a 3.5mm craniotomy was performed 
on the left hemisphere, 2mm lateral to the mid-sagittal suture and 2mm below the coronal suture. 
A 3mm rigid impactor (Leica Benchmark Stereotaxic Impactor) was placed perpendicularly to 
the exposed dura mater, and driven by an electromagnetic piston at 4 m/s. The impactor was 
driven into the cortical tissue to make a 2.5mm depression, and held there for 500ms. Following 
the injury, the scalp was closed with an absorbable suture, and lidocaine hydrochloride jelly and 
a triple antibiotic were applied to the area to provide a local anesthetic and prevent infection, 
respectively. Animals’ reflexes and breathing were monitored as they recovered and regained 
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consciousness prior to being placed back in their appropriate cage and back to the housing area. 
Sham animals received the same anesthesia and surgery (incision) without injury.  
2.3 Drug Administration 
Animals in DHF Group 1 and 2 received 5 single daily 5 mg/kg doses of 7,8-DHF 
intraperitoneally. Group 1 DHF animals received their first injection 1 hour post-CCI injury, and 
continued to receive treatment until day 4 post-injury (day 0-4 post-TBI), while Group 2 DHF 
animals received their first injection starting on day 2 post-injury, and continuing through day 6 
(day 2-6 post-TBI). Vehicle animals had the same treatment schedule as Group 1 DHF animals, 
but instead were administered 15% DMSO (dimethyl sulfoxide) intraperitoneally day 0-4.  
7,8-DHF was prepared immediately before injection to ensure that 7,8-DHF did not come out of 
solution. The proper amount of 7,8-DHF that was needed for a particular day was weighed out 
and dissolved in 100% DMSO first, then sterile PBS was added to make DMSO at 15%. The 
final 7,8-DHF concentration in vehicle for injection was 5 mg/ml, and was administered to the 
rats i.p. with a 26-gauge needle. The vehicle treatment was prepared by diluting 100% DMSO to 
15% DMSO with sterile PBS, and was administered in the same manner (26-gauge needle, i.p.), 
dosage, and concentration as 7,8-DHF treatments.  
All animals were also injected with 5-Bromo-2’-deoxyuridine (BrdU) to label dividing 
cells. D15 animals (sacrificed 15 days post-injury) received three doses of BrdU injection two 
hours apart (50mg/kg, i.p) at two days post-TBI. D28 animals received a single daily BrdU 
injection (50mg/kg, i.p.) for 7 days starting at 1 day post-TBI. BrdU was made in 0.9% saline 
with 0.007N NaOH at the concentration of 10mg/ml.  
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2.4 Tissue Processing 
Animals were sacrificed at day 15 or day 28 post-injury. Animals were anesthetized with 
5% isofluorane inhalation and transcardially perfused with 400 ml of 1x phosphate buffer 
solution (PBS), followed by 400 ml of 4% paraformaldehyde in PBS. The paraformaldehyde was 
prepared fresh on the day of perfusion. Once the perfusion was complete, the animal’s skull was 
opened and the brain was removed, and post-fixed in 4% paraformaldehyde in PBS at 4  for 48 
hours. The brains were then sliced into 60µm sections using a Leica Vibratome. Sections were 
sliced coronally in a rostro- caudal direction, and collected in five 24-well plates containing PBS 
with 0.02% sodium azide. Tissue sections were kept at 4°C until used for staining procedures.  
2.5 Immunohistochemistry Staining: Doublecortin (DCX) and Ki67 
Doublecortin (DCX) is a microtubule-binding protein associated with the migration of 
neuroblasts. DCX is an effective marker for adult neurogenesis as it has been demonstrated to be 
transiently expressed in proliferating progenitor cells and neuroblasts. As these newly generated 
cells develop and differentiate, their DCX expression declines and is replaced by mature 
neuronal markers, such as NeuN, a nuclear antigen (Brown et al., 2003). Ki-67 is a nuclear 
protein that is expressed in proliferating cells, and has been linked to ribosomal RNA(rRNA) 
synthesis (Bullwinkel et al., 2006). As such, it was employed in this experiment to assess cell 
proliferation in the hippocampus post-injury.  
To assess the number of DCX+ and Ki67+ cells, every eighth section extending from the 
rostro-caudal hippocampal dentate gyrus region from D15 animals was processed for DCX or 
Ki67 immunohistochemistry. The selected sections, contained individually in 24-well plates, 
were first washed with 1X PBS twice, and then quenched with 3% hydrogen peroxide for 1 hour 
at room temperature. Sections were then washed with a PBS-Triton mix (1X PBS + 0.3% 
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Triton100) once before blocking overnight with blocking buffer (5% normal horse serum in 
PBS- 0.3% Triton mix, as described previously) at 4°C on a shaker. The following day, the 
blocking buffer was removed and 250µl of primary antibody solution containing goat anti-DCX 
(1:1000, Santa Cruz) or rabbit anti-Ki67 (1:500, Abcam) in blocking buffer were added to each 
section, and allowed to incubate at 4°C on the shaker for 48 hours. 
After incubation with the primary antibody, sections were returned to room temperature, 
primary antibodies were removed, and sections were rinsed with the PBS- 0.3% Triton solution 3 
times. The sections were then blocked with the same blocking buffer for 3 hours at room 
temperature. Following blocking, 250µl/well of secondary antibody solutions (biotin-conjugated 
anti-goat 1:200 dilution for DCX; biotin-conjugated anti-rabbit 1:200 dilution for Ki67) in the 
same blocking buffer were added to the sections and allowed to incubate overnight at 4°C on a 
shaker. The next day, sections were brought back to room temperature and washed with 1X PBS 
3 times. An avidin-biotin complex (ABC; 1:200A, 1:200B) solution was prepared 30 minutes 
before use, and then added to the tissue sections for a 2 hour incubation at room temperature. 
The sections were then washed 3 times with 1X PBS.  
To prepare the DAB (Vector lab) solution, 10 mg of DAB powder were weighed out and 
added to 40 ml of 1X PBS and 17.5µl of 30% H2O2. Sections were incubated with the DAB 
solution for 2-5 minutes (or until staining could be seen in dentate gyrus under the light 
microscope), and then washed 3 times with 1X PBS. After staining was complete, the sections 
were mounted on glass slides, with 6 sections per slide placed in rostrocaudal order, and allowed 
to dry completely. Sections were counterstained with Nissl and coverslipped with Permount.  
 
 
46 
2.5.1 Stereological Cell Quantification 
A total of 20 brains (Table 2.1) were evaluated for DCX+ and Ki67+ hippocampal cell 
counts. To quantify the number of DCX+ cells in the ipsilateral and contralateral dentate gyrus 
and hilus regions, sections were manually counted with an Olympus Image System CAST 
program (Olympus, Denmark) using the optical fractionator sampling scheme.  This method 
allows counting particles within a uniform and systematic sample that is part of a known fraction 
of the region to be analyzed to estimate the total number of neurons in a particular section of the 
hippocampus.   
Five sequential sections per brain, 240µm apart, were examined. The region of interest 
(hippocampal dentate gyrus) was outlined while at the 4x objective, and the cells were counted at 
the 40x objective. For each section, an optical disector was used to count the number of neurons 
within a predetermined grid of x,y positions. The area of the unbiased counting frame (a / f) was 
known, and the rest of the positions in the grid were determined by stage-stepping intervals. 
Together these measurements are used to determine the area sampling fraction, (asf) = !/!(!" × !"). 
The dissector height was also known (h = 15µm) relative to the section thickness (t), and with all 
of these parameters, the total number of neurons in the object could be estimated using the 
following equation: 𝑛 = 𝛴𝑄⎺ ⋅ 𝑡/ℎ ⋅ 1/𝑎𝑠𝑓 ⋅ 1/𝑠𝑠𝑓 , where 𝛴𝑄⎺ is the number of cells counted, 
and ssf is the section-sampling fraction (0.125 in this study). 
DCX+ neurons were accounted for by their location in the hilus and location relative to 
the SGZ. The SGZ and inner third of the granular cell layer (GCL), the middle third of the GCL, 
and the outer third of the GCL were the three regions cells were counted to examine the extent of 
neuron migration (Figure 2.1). Ki67+ cells were located at 4x magnification and counted at 40x 
magnification, focusing through the entire section to account for cells that may have been darker 
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or lighter within different planes. Ki67+ cell counts were divided only by their presence within 
either the hilus or the SGZ + GCL region. 
 Type 1 early precursor cells, also referred to as radial glial cells, initiate the process of 
adult neurogenesis in the SGZ, and divide asymmetrically to produce type 2 (non-radial) cells 
Type 2 cells proliferate rapidly, and have the potential to differentiate into neurons or glial cells. 
Type 2 cells generate a more fate-committed type 3 cell (neural progenitor cell), which 
transitions from a proliferating neuroblast to an immature neuron (Ehninger and Kempermann, 
2008; Aimone et al., 2014). Immature neurons in the SGZ then migrate into the GCL; adult-born 
neurons, specifically, have been shown to preferentially migrate to the inner and middle layers of 
the GCL as they differentiate into mature granular cells, develop dendritic branches reaching 
towards the molecular layer, and develop axonal processes extending to the CA3 region. 
(Aimone et al., 2014). This integration and migration pattern can be disrupted in pathological 
conditions, such as schizophrenia, epilepsy, and neurodegenerative diseases (Ehninger and 
Kempermann, 2008).  
 Injury has also been shown to affect the outward migration of adult-born neurons in the 
SGZ. The migration of immature neurons into the GCL is not only accelerated in injury, but 
outward migration into the GCL is also increased, with some new neurons migrating beyond the 
GCL into the molecular layer following CCI. In addition to influencing outward migration, CCI 
injury has also been shown to increase complexity of dendrites in adult-born neurons, with an 
increase in the number of branch points closer to the soma (Villasana et al., 2015).  
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Figure 2.1 Regions of GCL and Hilus in Hippocampal Dentate Gyrus to Determine Neuron 
Migration. DCX+ cell counting in the GCL was divided into three parts: inner, middle, and 
outer, with the inner ⅓ including the SGZ, the site of adult neurogenesis. Image A shows a 4x 
magnification of the regions of interest within the DG. Image B shows a 40x magnification of 
the three layers within the DG, demonstrating individual cells within each layer. Red: DCX 
staining; Blue: DAPI staining. Image C shows the TBI-induced migration of immature adult-
born neurons from the SGZ into the GCL demonstrated by Villasana et al. (2015).  
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2.6 Differentiation Study 
2.6.1 Immunofluorescent Staining 
Incorporation of 5-Bromo-2’-deoxyuridine (BrdU) into dividing cells is generally used to 
detect adult neurogenesis and survival (Brown et al., 2003). The maturational fate of newly 
generated cells was determined by processing the sections for immunofluorescent double 
labeling with antibodies against BrdU and mature cell markers for neurons (NeuN), astrocytes 
(GFAP), or microglia (Iba1). To assess for BrdU+ cells, the sections were first washed with PBS, 
and then the DNA was denatured with 50% formamide for 60 minutes at 65°C. The sections 
were then rinsed with 2X SCC and incubated with 2N HCL for 30 minutes at 37°C.  
Following the denaturation process, sections were rinsed with 1X PBS, and subsequently 
quenched with 3% H2O2 for 1 hour at room temperature. Prior to blocking the sections overnight 
at 4°C (5% normal horse serum in 0.3% Triton), sections were rinsed with PBS. Following 
blocking, the sections were incubated with either mouse-anti BrdU primary antibody (1:200 
Dako) or rat-anti BrdU (1:200, Serotec) and mouse-anti NeuN (1:500, Chemicon), rabbit-anti 
GFAP (1:2000, Dako), or rabbit-anti Iba1 (1:1000, Wako) in PBS-Triton solution with 5% 
normal horse serum for 48 hours at 4°C. After 48 hours, sections were brought to room 
temperature, washed with PBS-Triton solution, and blocked overnight with the same blocking 
buffer. 
Secondary antibodies in blocking buffer were added the following day as follows: Alexa 
Fluor 488 anti-rat (1:200) and Alexa Fluor 568 anti-mouse (1:200) for BrdU/NeuN labeling, and 
Alexa Fluor 488 anti-mouse (1:200) and Alexa Fluor 568 anti-rabbit (1:200) for BrdU/GFAP and 
BrdU/Iba1 labeling. Sections incubated for 3 hours at room temperature, were washed with PBS, 
mounted on glass slides, and coverslipped with Vector shield.  
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2.6.2 Quantification of fluorescent double-labeled cells 
To quantify the percentage of BrdU+ cells in the dentate gyrus that co-labeled with cell 
type specific markers, sections were examined with a Zeiss 710 confocal microscope. BrdU cells 
were examined for the presence of co-labeling with cell specific markers, NeuN, GFAP, or Iba1. 
Only BrdU+ cells, for which the nucleus was unambiguously associated with a certain cell-type 
specific marker were considered co-labeled. The percentage of double-labeled cells was 
determined as the number of BrdU+/NeuN, BrdU+/GFAP, or BrdU+/Iba1+ cells versus the total 
number of BrdU+ cells. For each brain, a minimum of 100 BrdU+ cells were examined for their 
co-labeling with cell type specific markers in each subregion.  
2.7 Statistical Analysis 
The data gathered from immunohistochemistry procedures was analyzed using SPSS 
software. Data presented shows the mean and standard error of the mean. A two-way analysis of 
variance (ANOVA), followed by a Fisher least significant difference (LSD) test was performed 
to identify significance between treatment groups. P-values less than 0.05 determined 
significance. 
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Chapter 3: Results 
3.1 The effect of 7,8-DHF treatment on cell proliferation at subacute stage following TBI 
In this study, we use the proliferation marker Ki67 to assess whether DHF treatment can 
have a lasting effect on cell proliferation in the DG at 15 days post-injury.  The common staining 
pattern for Ki67+ cells within the DG is shown in Figure 3.1. Ki67 stained cells are located in 
the SGZ and inner 1/3 of the GCL, mostly in clusters as shown in Fig. 3.1B.  
Our previous studies have found that injured juvenile and adult rats have a significant 
increase in cell proliferation in the DG at 2 and 7 days post-injury compared to sham (Figure 
1.1), but no longer have a significant increase in proliferation by 14 days post-injury (Sun et al., 
2005). Using proliferation marker Ki67, we tested whether at the subacute stage following TBI 
(15 days), 7,8-DHF treatment has an effect on cell proliferation in the DG. We found that the 
number of Ki67 cells in the injured groups, including vehicle and both DHF treatment groups, 
are slightly higher than the sham group in the ipsilateral side of SGZ+GCL, however, the 
difference did not reach statistical significance. In the contralateral side of SGZ+GCL, slightly, 
but not significantly, higher number of Ki67+ cells are observed in the injured animals with DHF 
treatment (Fig 3.2).  In the hilus region, similar trend of Ki67+ cells are found as in the 
SGZ+GCL in both hemispheres (Fig. 3.3). The Ki67 data suggest that DHF did not affect cell 
proliferation at this time point.  
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Figure 3.1: 4x magnification (A) and 40x magnification (B) of Ki67+ staining within the 
hippocampal dentate gyrus. There was no significant difference in Ki67 staining, and hence, no 
significant difference in cellular proliferation, between treatment groups. Figure 3.7B illustrates 
the clumping pattern of proliferating cells that is characteristic for Ki67+ staining. 
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Figure 3.2:  Comparing Ki67+ cells in the ipsilateral and contralateral SGZ+GCL 15 days 
post-injury. There was no significant difference between treatment groups, however, all injured 
groups, particularly the DHG G2 group had a slightly higher number of Ki67+ cells. 
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Figure 3.3: Comparing Ki67+ cells in the ipsilateral and contralateral hilus regions 15 days 
post-injury. There was no significant difference between treatment groups. 
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3.2 The effect of 7,8-DHF on generation of new neurons at subacute stage following TBI 
DCX, an immature neuronal marker that labels neuroblast and migration new neurons, is 
widely used to assess generation of new neurons. In this study, to assess whether DHF treatment 
has an effect on neurogenesis in the DG, we processed brain sections taken from 15 days post-
injury with DCX staining and quantified the total number of DCX+ cells in the SGZ+GCL and 
hilus regions using unbiased stereological method. The DCX+ staining patterns that were 
commonly observed for each treatment group are shown in figure 3.4. In both DHF treatment 
groups, the cell body of DCX+ cells were densely distributed throughout the SGZ of the DG, 
with their dendrites extending outward to the molecular layer. There was also an increase in 
DCX+ cell density in vehicle DG, however, it was visibly less dense than either DHF treatment 
group. 
Within the SGZ+GCL region, a two-way ANOVA revealed a significant increase 
ipsilaterally in DCX+ cells in DHF Group 2 compared to sham (p = 0.0003), vehicle (p = 
0.0009), and DHF Group 1 (p = 0.0009) animals. Post-hoc comparisons confirmed these 
significant values (Figure 3.5).  Contralaterally, there was a significant increase in DCX+ cells in 
DHF Group 2 compared to vehicle (p = 0.01) and DHF Group 1 (p = 0.001), which was 
confirmed by a post-hoc comparison of pairwise differences among group means (Figure 3.5). In 
the hilus, a two-way ANOVA showed a significant increase in DCX+ cells ipsilaterally in DHF 
Group 2 compared to sham (p = 0.001) and DHF Group 1 (p = 0.02) animals, and in vehicle 
compared to sham (p = 0.01) animals (Figure 3.6). Figure 3.1 illustrates the differences in DCX+ 
staining within the four treatment groups. 
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Figure 3.4: Difference in DCX+ staining within the ipsilateral hemisphere of the 
hippocampal dentate gyrus of sham, vehicle, DHF Group 1, and DHF Group 2 following 
CCI injury. Both DHF treatment groups show increased density of DCX+ cells in the SGZ and 
into the GCL compared to sham and vehicle groups. Sham animals display the lowest density of 
DCX+ staining, and most DCX+ cells are restricted to the SGZ. DHF Treatment Group 2 had the 
most densely stained DCX+ cells within the ipsilateral SGZ+GCL and hilus regions. 
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Figure 3.5: Total DCX+ Cells in Subgranular Zone and Granular Cell Layer in the 
ipsilateral and contralateral hemispheres 15 days post-injury. There is a significant increase 
in DCX+ cells in the ipsilateral SGZ+GCL region of DHF Group 2 compared to all other 
treatment groups (*p<0.05). Contralaterally, there were significantly more DCX+ cells in sham 
animals compared to DHF Group 1, and significantly more DCX+ cells in DHF Group 2 
compared to DHF Group 1 (*p<0.05).  
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Figure 3.6: Comparing DCX+ cells of the hilus region in the ipsilateral and contralateral 
hemispheres 15 days post-injury. Ipsilaterally, there are significantly more DCX+ cells in DHF 
Group 2 and vehicle animals hilus region compared to sham animals, and more DCX+ cells in 
DHF Group 2 compared to DHF Group 1 (*p<0.05). Contralaterally, there were no significant 
differences. 
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3.2.1 7,8-DHF Treatment Group 2 increases migration of new neurons 
Adult-born neurons generated in the SGZ migrate outward to the granular cell layer 
where they become dentate granule cells and integrate into the existing circuitry (Zhao et al., 
2008). Migration of new neurons to the hilus or beyond the GCL to the molecular layer have 
been associated with pathological conditions, such as schizophrenia and epilepsy (Duan et al., 
2007; Gong et al., 2007). TBI has also been shown to increase the outward migration of new 
neurons following injury, however, unlike neuronal migration in schizophrenia or epilepsy, these 
new neurons are able to functionally integrate into the hippocampal cell network, and mature to 
have normal electrophysiological properties. These studies have suggested that newly generated 
neurons are able to participate in information processing once they have migrated from the SGZ 
into the surrounding circuitry (Villasana et al., 2015). 
In this study, we wanted to see if DHF influenced the migration of newly generated 
neurons from the SGZ to the GCL. There is a possibility that if more neurons migrate away from 
the SGZ and are able to functionally integrate into hippocampal circuitry, it may contribute to 
greater cognitive recovery. To examine this, the SGZ and GCL were divided into 3 regions to 
examine neuronal migration, with the inner third region containing the SGZ, which is a site of 
adult neurogenesis (Figure 2.1). Within the inner third of the SGZ + GCL, there was a significant 
increase in DCX+ cells ipsilaterally in DHF Group 2 compared to sham (p = 0.001), vehicle (p = 
0.002), and DHF Group 1 (p = 0.003) animals (Figure 3.4), which was confirmed in a post-hoc 
comparison. Contralaterally, there were significantly more DCX+ cells in DHF Group 2 
compared to vehicle (p = 0.04) and DHF Group 1 (p = 0.003) animals (Figure 3.7). 
Within the middle third of the GCL, DHF Group 2 once again had significantly more 
DCX+ cells than sham (p = 0.001), vehicle (p = 0.006), and DHF Group 1 (p = 0.004) animals, 
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ipsilaterally, and significantly more cells compared to vehicle (p = 0.004) and DHF Group 1(p = 
0.01), contralaterally. Sham animals also had significantly more DCX+ cells in the middle third 
of the GCL compared to vehicle (p = 0.003) and DHF Group 1(p = 0.009) animals 
contralaterally, indicating that the injury may have disrupted normal neuron migration in these 
groups (Figure 3.8). In the outer third layer, a two-way ANOVA and post-hoc comparison 
showed no significance between treatment groups (Figure 3.9).  
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Figure 3.7: Comparing the number of DCX+ cells of the ipsilateral and contralateral inner 
third of the SGZ+GCL 15 days post-injury.  There was a significant (*p < 0.05) increase in 
DCX+ cells on the ipsilateral side in DHF Group 2 compared to all other treatment groups. On 
the contralateral side, there were significantly (*p < 0.05) more DCX+ cells in DHF Group 2 
compared to vehicle and DHF Group 1. 
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Figure 3.8: Comparing the number of DCX+ cells in ipsilateral and contralateral middle 
third of GCL 15 days post-injury. There was a significant (*p < 0.05) increase in DCX+ cells 
in DHF Group 2 compared to all other treatment groups, ipsilaterally. Contralaterally, there was 
a significant (*p < 0.05) increase in DCX+ cells for both sham and DHF Group 2 animals 
compared to vehicle and DHF Group 1. 
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Figure 3.9: Comparing the number of DCX+ cells in the ipsilateral and contralateral outer 
third of GCL 15 days post-injury. There was no significant difference in the number of DCX+ 
cells among all groups. 
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3.3 The effect of 7,8-DHF treatment on cell type differentiation of newly generated cells 
following TBI 
Immunofluorescent double-labeling is an immunohistochemistry technique that localizes 
two specific antigens within a cell using fluorescently-labeled antibodies. For the purposes of 
this experiment, double-labeling allows us to determine the maturational fate of progenitor cells 
by observing the proteins the cell begins expressing as it matures, while it is still expressing its 
immature protein profile (Chen et al., 2010). We have demonstrated that the DHF has a 
significant effect on the generation of new neurons in the SGZ following TBI, and in this portion 
of the study we sought to determine the maturational fate of newly generated cells. Previous 
studies in our lab have shown that injured juvenile rats have a significant increase in newly 
generated cells differentiating into mature neurons, as demonstrated by higher percentage of co-
localization of BrdU+/NeuN+ cells in the SGZ (Sun et al., 2005).  
NeuN is a widely used marker for mature neurons which labels neuronal nuclei. Co-
labeling of BrdU and NeuN indicates neuronal maturation fate of newly generated cells. Under 
confocal microscopy, most of cells co-labeled with BrdU (green) and NeuN (red) are located in 
the SGZ and inner 1/3 of the GCL (Fig. 3.10). Scattered BrdU+/NeuN+ cells are also observed in 
the middle and outer 1/3 of the GCL. Co-labeling of two markers resulted in a yellow tone (Fig. 
3.10C). Using a two-way ANOVA and post-hoc analysis, it was determined that within the 
SGZ+GCL and hilus regions of the hippocampus there was no significant difference in the 
percentage of BrdU/NeuN co-localization between treatment groups. No BrdU/NeuN co-
localization was present for sham animals within the hilus region. As 3-month old adult rats were 
used in this study, the findings for vehicle-treated animals are consistent with previously 
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described studies (Sun et al., 2005), and also demonstrated that 7,8-DHF does not significantly 
increase differentiation of injury-induced proliferating cells into mature neurons.  
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Figure 3.10: Individual staining patterns of NeuN+ (3.10A) and BrdU+ (3.10B) cells and 
their merged colocalization (3.10C). There were no significant differences in the percentage of 
BrdU/NeuN col-ocalization between treatment groups (3.10D) within the SGZ+GCL or hilus 
regions. Regardless of injury or treatment, roughly the same percentage of proliferating cells 
differentiated into mature neurons. 
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Glial fibrillary acidic protein (GFAP) is an intermediate filament protein present in 
astrocytes within the CNS. Astrocytes are a type of star-shaped glial cell in the CNS that 
facilitate communication between neurons by absorbing and secreting neurotransmitters within 
the tripartite synapse, and maintaining the BBB (Araque et al., 1999). Studies have shown the 
fate of proliferating cells proximal to the injury site in mice is predominantly astrocytic at 60 
days post- CCI injury, forming a astrogliotic scar at the site of injury, and demonstrating that 
newly generated cells contribute to cellular remodeling following TBI (Kernie et al., 2001). A 
similar increase in BrdU+/GFAP+ cells is observed in the SGZ following injury in both adult 
rats and mice (Kernie et al., 2001; Sun et al., 2005). In this portion of the study, we sought to 
determine if 7,8-DHF treatment affected the differentiation of newly generated cells into 
astrocytes following injury. 
Astrocytes are star-shaped, with multiple processes extending from the cell body, and 
wrapping around surrounding neurons (Figure 3.11 C). The staining pattern of GFAP+ cells is 
demonstrated in figure 3.11 A. Progenitor cells that co-expression GFAP and BrdU following 
CCI injury will likely differentiate into astrocytes. Type 1 progenitor cells in the SGZ also 
express GFAP, but can be differentiated from astrocytes in the SGZ as Type 1 progenitors also 
express Nestin (Kriegstein and Alvarez-Buylla, 2009). The total number of independent BrdU+ 
and colocalized BrdU+/GFAP+ cells was counted within the SGZ+GCL and hilus regions to 
determine the percent co-localization of BrdU+/GFAP+. A two-way ANOVA revealed no 
significant difference between treatment groups within the SGZ+GCL region, but a significant 
increase in DHF Treatment Group 2 compared sham (*p = 0.031) and vehicle (*p = 0.023) 
animals within the hilus region. A Fisher least significant difference (LSD) post-hoc comparison 
confirmed these results. Once again, sham animals had no co-localization within the hilus region. 
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Figure 3.11: Individual staining patterns of GFAP+ (3.11A) and BrdU+ (3.11B) cells and 
their merged colocalization (3.11C). There was no significant difference in the percentage of 
BrdU+/GFAP+ co-labeling within the SGZ+GCL region (3.11D), however there were 
significantly (*p<0.05) higher percentage of BrdU+/GFAP+ cells within the hilus region of DHF 
Treatment Group 2 animals compared to sham and vehicle. 
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Finally, we assessed the percentage of co-localization of BrdU+/Iba1+ cells in the DG to 
determine if 7,8-DHF influenced the differentiation of injury-induced proliferating cells into 
microglia. Iba1 is a widely used marker for microglia. It labels ionized calcium-binding adaptor 
molecule 1 expressed by microglial cells. Microglia are a type of glial cell commonly activated 
by inflammatory pathways following injury, and are crucial to the central nervous system’s 
immune response. Over-activation of microglia, however, can have negative effects, including 
chronic pain and destruction of neurons, leading to neurodegenerative disorders (Wood, 2002).  
Progenitor cells that co-express BrdU and Iba1 suggest differentiation into microglia 
following injury. Microglia exist in ramified (or resting) and activated forms, which are reflected 
in their morphology. Ramified microglia have a small cell body and long, intricate cellular 
processes or arborization, while microglia activated by disruptions in homeostasis have 
shortened projections with reduced complexity and a larger cell body (Kettenmann et al., 2011). 
Activated microglia were observed in this study, as shown in red in figure 3.12 A, as a result of 
the CCI injury. 
The percent BrdU/Iba1 co-localization was measured by counting independent BrdU+ 
cells and cells co-labeled with BrdU and Iba1+ cells. In the SGZ+GCL region, a two-way 
ANOVA and Fisher LSD post-hoc analysis has shown that injured animals with vehicle 
treatment had a significantly higher percentage co-localization of BrdU+/Iba1+ neurons 
compared to sham animals within the SGZ-GCL region (*p=0.037). Within the hilus, vehicle 
(*p=0.01) and both treatment groups (DHF G1 *p= 0.012; DHF G2 *p=0.007) had a 
significantly higher percentage of BrdU+/Iba1+ co-localization compared to sham animals. No 
BrdU/Iba1 co-labeled cells were found within the SGZ-GCL region in sham. 
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Figure 3.12: Individual staining patterns of Iba1+ (3.12A) and BrdU+ (3.12B) cells and 
their merged colocalization (3.12C). There were significantly (*p<0.05) more BrdU+/Iba1+ 
cells in vehicle animals compared to sham animals within the SGZ-GCL region. There was no 
colocalization within the hilus region of sham animals. Every other treatment group (including 
vehicle) had significantly (*p<0.05) higher percentage of BrdU+/Iba1+ cells than the sham 
animal. 
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Chapter 4: Discussion 
4.1 Summary 
The goal of this study was to examine the effects of 7,8-DHF on proliferation, 
neurogenesis, neural migration, and neural differentiation within the hippocampal DG following 
CCI injury. Injury-induced cellular proliferation, neurogenesis, and migration were examined at 
15 days post-injury, and differentiation of newly generated cells was examined 28 days post-
injury. In this study we found that 7,8-DHF did not have a significant effect on proliferation in 
the SGZ+GCL or hilus regions in the subacute stage. However, there was an increasing trend in 
the SGZ+GCL region among treatment groups, demonstrated in figure 3.8, in which all injured 
animals experience increased proliferation, and both DHF treatment groups had increased 
proliferation compared to vehicle animals. We also found that 5 doses of 7,8-DHF treatment 
starting 48hrs post-CCI injury caused a significant increase in neurogenesis in the SGZ+GCL 
and hilus regions of the dentate gyrus, and an increase in migration in the SGZ+GCL compared 
to sham and vehicle animals, as well as animals treated with 5 doses of 7,8-DHF beginning 1hr 
post-injury.  
In the differentiation study, neither vehicle nor DHF-treated animals demonstrated an 
increase in differentiation of newly generated cells into mature neurons within both SGZ-GCL 
and hilus regions. Conversely, all injured animals, regardless of vehicle or DHF treatment, had 
an increase in BrdU/GFAP and BrdU/Iba1 labeled cells in the hilus, suggesting that the injury-
induced increase of BrdU-labeled cells in the hilus region are mainly glial cell types, regardless 
of treatment.  
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4.2 Discussion 
Our study found that 7,8-DHF did not have a significant effect on proliferation at day 15 
post-injury. Previous studies in our lab have shown that there is a significant increase in 
proliferation of the SGZ at 2 and 7 days post-injury in adult adults, but levels are no longer 
significantly elevated by day 14 post-injury (Figure 1.1; Sun et al., 2005). Our results for sham 
and vehicle at 15 days post-injury are consistent with the 14 day post-injury data of this study, 
and the lack of significantly elevated Ki67+ cells in both DHF treatment groups suggest that by 
15 days post-injury, 7,8-DHF does not significantly influence proliferation at this time point 
post-TBI. This is consistent with another group that studied DHF effects on proliferation 
following TBI, which found that DHF did not cause any significant increase in cell proliferation 
at 2 weeks post-injury (Zhao et al., 2015).  
Multiple studies have shown that growth factors play an important role in mediating 
neurogenesis, and have elevated expression during brain development (Caday et al., 1990). 
Experiments that supplied exogenous basic fibroblast growth factor (bFGF) following lateral 
fluid percussion injury have shown a significant increase in proliferation of the SGZ and 
subventricular zone (SVZ) at 7 days post-injury compared to both sham and vehicle animals 
(Sun et al., 2009). Although 7,8-DHF is not a growth factor, it binds to the same receptor, TrkB, 
as growth factor BDNF, and mimics its downstream effects. Our study did not include 
assessment at 7 days post-injury, but given previous studies and 7,8-DHF’s growth-factor like 
effects, one would expect that it may affect cellular proliferation at early time points post-injury. 
Future studies in our lab will include an assessment of proliferation at 7 days post-injury to 
confirm or reject this hypothesis. 
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It is worth noting that although injured brains have increased proliferation up to 2 weeks 
post-injury, long-term cell survival is diminished in injured brains compared to sham. This is 
supported by the fact that only 46% of newly generated neurons in the dentate gyrus survive up 
to 10 week post-injury, while sham animals exhibit 65% survival of new neurons in the same 
time frame, suggesting that the injured brain environment is not well-suited for long-term cell 
survival (Sun et al., 2007). One explanation for the poor environment an injured brain provides 
for cell survival may be an insufficient level of neurotrophins. Such environments are typical of 
brains in the initial stages of neurodegenerative diseases such as Alzheimer’s, but limited 
neurotrophic support is also observed in cognitive impairments and brain trauma (Sun et al., 
2007).  
According to our results, intraperitoneal administration of 5mg/kg of 7,8-DHF, starting at 
2 days post-injury for 5 daily doses significantly increased neurogenesis and migration in the 
hippocampal dentate gyrus compared to sham, vehicle, and DHF Group 1 animals. Previous 
studies in our lab have shown that injured juvenile (vehicle) brains experience a more robust 
neurogenic response than adult or aged rats (Sun et al., 2005). Several groups have had 
conflicting results on whether TBI produces a significant increase in neurogenesis, which is due, 
in large part, to the variation in injury severity in different TBI models. In a mouse CCI model, a 
recent study has reported that mild TBI did not affect cell proliferation in the DG, while 
moderate TBI caused an increase in cell proliferation, but no neurogenesis. Only severe TBI 
resulted in an increase of both proliferation and neurogenesis (generation of new mature 
neurons) (Wang et al., 2015). 
In the current study, we did not observe a significant increase in neurogenesis in vehicle 
animals, which is consistent with the moderate CCI injury we performed and Wang et al’s 2015 
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study. Although the lack of significant increase in proliferation is consistent with our lab’s 
previous studies (Sun et al., 2005), because we did not test proliferation at day 7 post-injury, we 
cannot be certain that the moderate TBI, by Wang’s description above, was performed, as we did 
not measure proliferation during a time period (day 2-7) that TBI-induced proliferation is known 
to be significantly increased. 
A recent study examined the effects of 7,8-DHF on adult mice also found that DHF 
significantly increased the number of DCX+ cells in the SGZ and inner ⅓ layer of the GCL at 2 
weeks post-injury (Zhao et al., 2015). This group employed a different DHF treatment strategy 
and a mouse CCI model that was different from our study. In this study, injured animals received 
daily DHF injections for the weeks following injury until they were sacrificed. It was reported 
that DHF-treated injured animals have significantly more DCX+ cells compared to sham 
animals, and sham animals treated with DHF did not have a significant change in DCX+ cell 
density, suggesting that DHF’s neurogenic effects are injury-(or pathology) related (Zhao et al., 
2015). 
By increasing the number of surviving cells at 15 days post injury, it is possible that 
injured brains treated in this manner will have more surviving cells long-term that can 
successfully integrate into the hippocampal circuitry. Adult neurogenesis is involved in 
hippocampal-dependent learning, thus the combination of injury and 7,8-DHF-induced 
neurogenesis may result in better cognitive outcomes (Gould et al., 1999). This is supported by 
the fact that enhanced neurogenesis in this region from injections of basic fibroblast growth 
factor (bFGF), a neurotrophic factor, post-injury has been shown to contribute to cognitive 
improvement in the Morris Water Maze (Sun et al., 2009).  
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DHF treatment group 2 consistently having significantly more DCX+ cells in the DG 
than DHF group 1, which received DHF injections beginning 1 hour post-injury, may be due to a 
variety of reasons. As described above and shown in Figure 1.1, the proliferative response in the 
DG following injury is highest at 48 hours post-injury and continues for up to 7 days (Sun et al., 
2005). It is possible that complementing the endogenous proliferative response with 7,8-DHF 
over the same time period (day 2-6) of increased proliferation contributes to the significant 
increase in DCX+ cells at 15 dpi.  
Additionally, endogenous BDNF levels are significantly upregulated at 12 hours post-
injury, but start declining at 24 hours, and are not at significantly elevated levels by 36 hours 
post-injury. The necrosis pathway, associated with calpain proteases, is also quickly activated in 
the hours immediately following injury, and employs neurofilaments and spectrins as primary 
substrates, leading to the disruption of cell transport and structure, and ultimately cell death 
(McAllister, 2011). Beginning treatment once initial BDNF and calpain pathways have subsided 
may aid in harnessing 7,8-DHF’s neurotrophic-like effects, as surviving cells may be able to 
properly utilize it once the inflammatory responses are reduced. The initial response of BDNF 
following injury is to initiate a neuroprotective response, rather than a regenerative effect (Zhao 
et al., 2015). Beginning DHF treatment during the initial spike in BDNF levels may help protect 
existing dendrites from injury, but may not contribute as much to the regenerative response that 
is established later on. Finally, BDNF binds to the TrkB receptor with a higher affinity (Kd = 
1.7nm) than 7,8-DHF (Kd = 15.4nm), so it is possible that BDNF outcompetes 7,8-DHF for 
TrkB receptors within the first 24-36 hours following injury. 
TBI has been shown to accelerate the outward migration of newly generated neurons 
post-injury, migrating from the subgranular zone (SGZ) to the granular cell layer (GCL), 
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specifically in the ipsilateral hemisphere. Injury, however, does not increase migration into the 
hilus region (Villasana et al., 2015). Our results confirmed this outward migration in DHF Group 
2 animals, as this treatment group exhibited significant increase in DCX+ cells ipsilaterally in the 
middle third layer of the GCL, and though the increase was not significant in the outer third 
layer, there was a noticeable increase in DCX+ cells for DHF Group 2 animals in this layer 
compared to sham and DHF Group 1 animals. This outward migration from the dentate gyrus 
towards the outer GCL region may aid in the integration of dendrites into the existing CA1 
hippocampal circuitry, and contribute to cognitive recovery (Gould et al., 1999).  
Vehicle animals did not have a statistically significant increase in DCX+ cells in the 
middle and outer layers of the GCL, but did have increased cell counts compared to sham and 
DHF Group 1 animals. One study has shown that untreated injured animals have significantly 
increased migration into the ipsilateral GCL region compared to sham animals. (Villasana et al., 
2015). Our results are not consistent with that study. Although vehicle animals had increased 
levels of DCX+ cells in all three regions of the SGZ+GCL compared to sham, none of the 
differences were statistically significant. This discrepancy may be attributed to differences in 
measurement strategies (distance from SGZ). 
The maturational fates of the neural progenitor cells following injury and DHF treatment 
provide insight into the role new neurons will play in the weeks following injury. Previous 
studies in our lab have demonstrated that newly generated cells post-injury have a higher 
percentage differentiating into glial cells in adult rats and a higher percentage differentiation into 
mature neurons in juvenile rats (Sun et al., 2005). Our results were consistent with these 
findings, as there was no statistically significant difference in percentage co-localization of 
BrdU+/NeuN+ between treatment groups within the SGZ+GCL or hilus regions, but there was a 
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significant increase in BrdU+/GFAP+ cells in the hilus region of DHF Group 2 animals and a 
significant increase in BrdU+/Iba1+ cells in the hilus region of all injured animals. If these 
mature neurons survive, they will functionally incorporate into the surrounding circuitry 
(Villasana et al., 2015). 
While there was no statistically significant difference in the percentage of BrdU+/GFAP+ 
co-localization within the SGZ+GCL region, DHF Treatment Group 2 had significantly a 
significantly higher percentage of colocalization than both sham and vehicle in the hilus region. 
GFAP is an astrocytic marker, and cells expressing this protein will differentiate into astrocytes. 
Astrocytes are a type of glial cell found in both the brain and spinal cord, and function as part of 
the tripartite synapse, facilitating the passage of neurotransmitters to and from synapses, and 
providing support to endothelial cells that line the BBB. Although astrocytes were once thought 
of as space fillers in the brain, they have been found to play a crucial role in neuronal network’s 
communication (Araque et al., 1999). In addition to its role in signaling, astrocytes have also 
been shown to promote oligodendrogenesis following damage to white matter through the BDNF 
signaling pathway. Oligodendrogenesis promotes the growth of oligodendrocytes, which 
contribute to the creation of myelin that wraps around axons to ensure rapid signaling (Miyamoto 
et al., 2015). 
The significant increase in BrdU+/GFAP+ cells in DHF Treatment Group 2 in the hilus 
region may aid in the reestablishment of communication between new and/or existing neuron 
and oligodendrogenesis. The entire dentate gyrus surrounds the CA3 region of the hippocampus, 
but the hilus in particular outlines it closely. It is possible that an increase in astrocytes in this 
region promotes the integration of axons from neurons in the SGZ with neurons of the CA3 
region. 
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Finally, there was a significant difference in BrdU+/Iba1+ colocalization in vehicle 
animals compared to sham in the SGZ+GCL, and also for all treatment groups (including 
vehicle) compared to sham within the hilus region. Cells that co-express BrdU/Iba1 indicate that 
they are proliferative microglia cells. Microglia are related to cells from the macrophage lineage, 
and perform similar functions to their relatives within the CNS, phagocytosing debris and 
intruders. Microglia are also the first cells to respond to injury within the CNS; they 
subsequently release cytotoxic mediators and generate an inflammatory response (Gehrmann et 
al., 1995). Following an injury, or in some autoimmune diseases, microglia can rapidly 
proliferate, over activate, and ultimately lead to neurodegeneration (Wood, 2002). 
In both the SGZ-GCL and hilus regions, it is not surprising that the sham animal had very 
few Iba1+ cells and no co-localization at all. The animal had not experienced injury, so 
presumably, there was no experimental reason for microglia to be in the activated form. Vehicle 
animals, understandably, had a statistically significant increase in BrdU+/Iba1+ percent co-
localization compared to sham. While it was not statistically significant, vehicle animals did 
have a greater percentage of co-localization within the SGZ-GCL region compared to both DHF 
treatment groups. This suggests that, within this region, 7,8-DHF may keep the inflammatory 
response low. 
4.3 Conclusions 
The findings in the current study support the therapeutic potential for the use of 7,8-
dihydroxyflavone in post-TBI treatment. Due to its small size (254Da) and substantial half-life 
(134 minutes), 7,8-DHF is able to cross the BBB and effectively act as a TrkB agonist, 
supporting the generation and migration of new neurons, astrocytes, and microglia. Finding 
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feasible treatment options, like 7,8-DHF, that can combat neuronal loss following injury is 
crucial to the recovery and cognitive outcomes of TBI patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
List of References 
1. Araque, Alfonso, et al. "Tripartite synapses: glia, the unacknowledged partner." Trends in 
neurosciences 22.5 (1999): 208-215 
2. Aimone, James B., et al. "Regulation and function of adult neurogenesis: from genes to 
cognition."Physiological reviews 94.4 (2014): 991-1026. 
3. Baseri, Babak, et al. "Activation of signaling pathways following localized delivery of 
systemically administered neurotrophic factors across the blood–brain barrier using 
focused ultrasound and microbubbles." Physics in medicine and biology 57.7 (2012): 
N65. 
4. Bergami, Matteo, et al. "Deletion of TrkB in adult progenitors alters newborn neuron 
integration into hippocampal circuits and increases anxiety-like behavior." Proceedings 
of the National Academy of Sciences 105.40 (2008): 15570-15575. 
5. Book, CDC CDC Injury Fact. "Atlanta, GA: US Department of Health and Human 
Services, CDC." National Center for Injury Prevention and Control(2006). 
6. Brown, Jason P., et al. "Transient expression of doublecortin during adult neurogenesis." 
Journal of Comparative Neurology 467.1 (2003): 1-10. 
7. Bullwinkel, Jörn, et al. "Ki 67 protein is associated with ribosomal RNA transcription in 
quiescent and proliferating cells." Journal of cellular physiology206.3 (2006): 624-635. 
8. Caday, Cornelio G., et al. "Fibroblast growth factor (FGF) levels in the developing rat 
brain."Developmental Brain Research 52.1 (1990): 241-246. 
9. Chan, Jason P., et al. "Depletion of central BDNF in mice impedes terminal 
differentiation of new granule neurons in the adult hippocampus." Molecular and 
Cellular Neuroscience 39.3 (2008): 372-383. 
10. Chauhan, Neelima B. "Chronic neurodegenerative consequences of traumatic brain 
injury." Restorative neurology and neuroscience 32.2 (2013): 337-365. 
11. Chen, Xiao, Dan-Bi Cho, and Ping-Chang Yang. "Double staining 
immunohistochemistry." N Am J Med Sci 2.5 (2010): 241-245. 
12. Chiaretti, Antonio, et al. "Correlation between neurotrophic factor expression and 
outcome of children with severe traumatic brain injury." Intensive care medicine 29.8 
(2003): 1329-1338. 
94 
13. Chirumamilla, S., et al. "Traumatic brain injury induced cell proliferation in the adult 
mammalian central nervous system." Journal of neurotrauma 19.6 (2004): 693-703. 
14. Chodobski, Adam, Brian J. Zink, and Joanna Szmydynger-Chodobska. “Blood-Brain 
Barrier Pathophysiology in Traumatic Brain Injury.” Translational stroke research 2.4 
(2011): 492–516. PMC. Web. 9 Jan. 2016. 
15. Clelland, C. D., et al. "A functional role for adult hippocampal neurogenesis in spatial 
pattern separation." Science 325.5937 (2009): 210-213. 
16. Cohen, Stanley, Rita Levi-Montalcini, and Viktor Hamburger. "A nerve growth-
stimulating factor isolated from sarcomas 37 and 180." Proc Natl Acad Sci USA 40.10 
(1954): 1014-1018. 
17. Cooke, S. F., and T. V. P. Bliss. "Plasticity in the human central nervous system." Brain 
129.7 (2006): 1659-1673. 
18. Dash, P. K., S. A. Mach, and A. N. Moore. "Enhanced neurogenesis in the rodent 
hippocampus following traumatic brain injury."Journal of neuroscience research 63.4 
(2001): 313-319. 
19. Deng, Wei, et al. "Adult-born hippocampal dentate granule cells undergoing maturation 
modulate learning and memory in the brain." The Journal of neuroscience 29.43 (2009): 
13532-13542.  
20. Dieni, Sandra, et al. "BDNF and its pro-peptide are stored in presynaptic dense core 
vesicles in brain neurons." The Journal of cell biology 196.6 (2012): 775-788. 
21. Dikranian, K., et al. "Mild traumatic brain injury to the infant mouse causes robust white 
matter axonal degeneration which precedes apoptotic death of cortical and thalamic 
neurons."Experimental neurology 211.2 (2008): 551-560. 
22. Duan, Xin, et al. "Disrupted-In-Schizophrenia 1 regulates integration of newly generated 
neurons in the adult brain." Cell 130.6 (2007): 1146-1158. 
23. ELDADAH, BASIL A., and ALAN I. FADEN. "Caspase pathways, neuronal apoptosis, 
and CNS injury." Journal of neurotrauma 17.10 (2000): 811-829. 
24. Emery, Dana L., et al. "Newly born granule cells in the dentate gyrus rapidly extend 
axons into the hippocampal CA3 region following experimental brain injury." Journal of 
neurotrauma 22.9 (2005): 978-988. 
95 
25. Farkas, Orsolya, and John T. Povlishock. "Cellular and subcellular change evoked by 
diffuse traumatic brain injury: a complex web of change extending far beyond focal 
damage." Progress in brain research 161 (2007): 43-59. 
26. Fitzgerald P.B, Fountain S, Daskalakis Z.J. A comprehensive review of the effects of 
rTMS on motor cortical excitability and inhibition. Clin Neurophysiol. 2006;117:2584–
2596. 
27. Friedlander, Robert M. "Apoptosis and caspases in neurodegenerative diseases." New 
England Journal of Medicine 348.14 (2003): 1365-1375. 
28. Gao, Xiang, and Jinhui Chen. "Conditional knockout of brain-derived neurotrophic factor 
in the hippocampus increases death of adult-born immature neurons following traumatic 
brain injury." Journal of neurotrauma26.8 (2009): 1325-1335. 
29. Gehrmann, Jochen, Yoh Matsumoto, and Georg W. Kreutzberg. "Microglia: intrinsic 
immuneffector cell of the brain." Brain Research Reviews 20.3 (1995): 269-287. 
30. Gomazkov, O. A. "Neurotrophins: The therapeutic potential and concept of 
minipeptides." Neurochemical Journal 6.3 (2012): 163-172. 
31. Gong, Chao, et al. "Reelin regulates neuronal progenitor migration in intact and epileptic 
hippocampus." The Journal of neuroscience 27.8 (2007): 1803-1811. 
32. Gould, Elizabeth, et al. "Neurogenesis in adulthood: a possible role in learning." Trends 
in cognitive sciences 3.5 (1999): 186-192. 
33. Guskiewicz, Kevin M., et al. "Association between recurrent concussion and late-life 
cognitive impairment in retired professional football players."Neurosurgery 57.4 (2005): 
719-726. 
34. Harborne, Jeffrey B., and Christine A. Williams. "Advances in flavonoid research since 
1992."Phytochemistry 55.6 (2000): 481-504. 
35. Hicks, R. R., et al. "Expression of trkB mRNA is altered in rat hippocampus after 
experimental brain trauma." Molecular brain research 59.2 (1998): 264-268. 
36. Hicks, R. R., et al. "Mild experimental brain injury differentially alters the expression of 
neurotrophin and neurotrophin receptor mRNAs in the hippocampus." Experimental 
neurology 160.2 (1999): 469-478. 
96 
37. Holmin, Staffan, et al. "Delayed cytokine expression in rat brain following experimental 
contusion." Journal of neurosurgery 86.3 (1997): 493-504. 
38. Hyder, Adnan A., et al. "The impact of traumatic brain injuries: a global 
perspective."NeuroRehabilitation-An Interdisciplinary Journal22.5 (2007): 341-354. 
39. Jang, Sung-Wuk, et al. "A selective TrkB agonist with potent neurotrophic activities by 7, 
8-dihydroxyflavone." Proceedings of the National Academy of Sciences 107.6 (2010): 
2687-2692. 
40. Kadhim, Hazim J., Jean Duchateau, and Guillaume Sébire. "Cytokines and brain injury: 
invited review." Journal of intensive care medicine 23.4 (2008): 236-249. 
41. Kaplan, David R., and Freda D. Miller. "Neurotrophin signal transduction in the nervous 
system." Current opinion in neurobiology 10.3 (2000): 381-391. 
42. Kaplan, Gary B., Jennifer J. Vasterling, and Priyanka C. Vedak. "Brain-derived 
neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their 
comorbid conditions: role in pathogenesis and treatment."Behavioural pharmacology 
21.5-6 (2010): 427-437. 
43. Kettenmann, Helmut, et al. "Physiology of microglia." Physiological reviews 91.2 
(2011): 461-553. 
44. Kernie, Steven G., Trent M. Erwin, and Luis F. Parada. "Brain remodeling due to 
neuronal and astrocytic proliferation after controlled cortical injury in mice." Journal of 
neuroscience research66.3 (2001): 317-326. 
45. Kornack, David R., and Pasko Rakic. "Continuation of neurogenesis in the hippocampus 
of the adult macaque monkey." Proceedings of the National Academy of Sciences 96.10 
(1999): 5768-5773. 
46. Kriegstein, Arnold, and Arturo Alvarez-Buylla. "The glial nature of embryonic and adult 
neural stem cells." Annual review of neuroscience 32 (2009): 149. 
47. Laskowitz, Daniel, and Gerald Grant, eds. Translational Research in Traumatic Brain 
Injury. Vol. 57. CRC Press, 2015. 
48. Lee, Jaewon, Wenzhen Duan, and Mark P. Mattson. "Evidence that brain derived 
neurotrophic factor is required for basal neurogenesis and mediates, in part, the 
97 
enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice." 
Journal of neurochemistry 82.6 (2002): 1367-1375. 
49. Leo P, McCrea M. Epidemiology. In: Laskowitz D, Grant G, editors. Translational 
Research in Traumatic Brain Injury. Boca Raton (FL): CRC Press/Taylor and Francis 
Group; 2016. Chapter 1. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK326730/ 
50. Lessmann, Volkmar, Kurt Gottmann, and Marzia Malcangio. "Neurotrophin secretion: 
current facts and future prospects." Progress in neurobiology 69.5 (2003): 341-374. 
51. Levi-Montalcini, Rita. "The nerve growth factor: thirty-five years later."Bioscience 
Reports 7.9 (1987): 681-699. 
52. Levine, Eric S., et al. "Brain-derived neurotrophic factor modulates hippocampal synaptic 
transmission by increasing N-methyl-D-aspartic acid receptor activity." Proceedings of 
the National Academy of Sciences 95.17 (1998): 10235-10239. 
53. Liu, Chaoyang, Chi Bun Chan, and Keqiang Ye. "7, 8-dihydroxyflavone, a small 
molecular TrkB agonist, is useful for treating various BDNF-implicated human 
disorders." Translational neurodegeneration 5.1 (2016): 1 
54. Liu, Xia, et al. "Biochemical and biophysical investigation of the brain-derived 
neurotrophic factor mimetic 7, 8-dihydroxyflavone in the binding and activation of the 
TrkB receptor." Journal of Biological Chemistry 289.40 (2014): 27571-27584. 
55. Lu, Yuan, Kimberly Christian, and Bai Lu. "BDNF: a key regulator for protein synthesis-
dependent LTP and long-term memory?." Neurobiology of learning and memory 89.3 
(2008): 312-323. 
56. Marco Salazar, Paola. "The role of neurotrophins and neurotrophin receptors in the 
pathogenesis of neurodegeneration and neuroregeneration." (2014): 186. 
57. Marco-Salazar, P., et al. "Mapping of Neurotrophins and their Receptors in the Adult 
Mouse Brain and their Role in the Pathogenesis of a Transgenic Murine Model of Bovine 
Spongiform Encephalopathy." Journal of comparative pathology 150.4 (2014): 449-462. 
58. Mattson, Mark P., and Stephen W. Scheff. "Endogenous neuroprotection factors and 
traumatic brain injury: mechanisms of action and implications for therapy." Journal of 
neurotrauma 11.1 (1994): 3-33. 
98 
59. McAllister, Thomas W. "Neurobiological consequences of traumatic brain injury." 
Dialogues in clinical neuroscience 13.3 (2011): 287. 
60. Menon, David K. et al. Position Statement: Definition of Traumatic Brain Injury. 
Archives of Physical Medicine and Rehabilitation , Volume 91 , Issue 11 , 1637 - 1640 
61. Merlio, Jean-Philippe, et al. "Increased production of the TrkB protein tyrosine kinase 
receptor after brain insults." Neuron 10.2 (1993): 151-164. 
62. Miyamoto, Nobukazu, et al. "Astrocytes promote oligodendrogenesis after white matter 
damage via brain-derived neurotrophic factor." The Journal of Neuroscience 35.41 
(2015): 14002-14008. 
63. Muccigrosso, Megan M., et al. "Cognitive Deficits Develop 1 month after Diffuse Brain 
Injury and are Exaggerated by Microglia-Associated Reactivity to Peripheral Immune 
Challenge." Brain, Behavior, and Immunity (2016). 
64. Nathoo, Narendra, et al. "Influence of apoptosis on neurological outcome following 
traumatic cerebral contusion." Journal of neurosurgery 101.2 (2004): 233-240. 
65. Oyesiku, Nelson M., et al. "Regional changes in the expression of neurotrophic factors 
and their receptors following acute traumatic brain injury in the adult rat brain." Brain 
research 833.2 (1999): 161-172. 
66. Phillips, Linda L., and Thomas M. Reeves. "Interactive pathology following traumatic 
brain injury modifies hippocampal plasticity." Restorative neurology and neuroscience 
19.3-4 (2001): 213-235. 
67. Pillai, Anilkumar. "Brain-derived neurotropic factor/TrkB signaling in the pathogenesis 
and novel pharmacotherapy of schizophrenia." Neurosignals16.2-3 (2008): 183-193. 
68. Price, Raymond D., et al. "Advances in small molecules promoting neurotrophic 
function." Pharmacology & therapeutics 115.2 (2007): 292-306. 
69. Raghupathi, Ramesh. "Cell death mechanisms following traumatic brain injury." Brain 
pathology 14.2 (2004): 215-222. 
70. Roux, Philippe P., and Philip A. Barker. "Neurotrophin signaling through the p75 
neurotrophin receptor." Progress in neurobiology 67.3 (2002): 203-233. 
99 
71. Sandhir, Rajat, Gregory Onyszchuk, and Nancy EJ Berman. "Exacerbated glial response 
in the aged mouse hippocampus following controlled cortical impact injury." 
Experimental neurology 213.2 (2008): 372-380 
72. Scharfman, Helen, et al. "Increased neurogenesis and the ectopic granule cells after 
intrahippocampal BDNF infusion in adult rats." Experimental neurology 192.2 (2005): 
348-356. 
73. Schaub, Rainer T., et al. "Serum nerve growth factor concentration and its role in the 
preclinical stage of dementia." American Journal of Psychiatry(2014). 
74. Shervin R, Shivanand P L. Traumatic Brain Injury and Potential for Neuromodulation. 
In: Laskowitz D, Grant G, editors. Translational Research in Traumatic Brain Injury. 
Boca Raton (FL): CRC Press/Taylor and Francis Group; 2016. Chapter 17. Available 
from: http://www.ncbi.nlm.nih.gov/books/NBK326732/ 
75. Shohami, Esther, et al. "Oxidative stress in closed-head injury: brain antioxidant capacity 
as an indicator of functional outcome." Journal of Cerebral Blood Flow & Metabolism 
17.10 (1997): 1007-1019. 
76. Siegel, George J., and Neelima B. Chauhan. "Neurotrophic factors in Alzheimer’s and 
Parkinson’s disease brain." Brain Research Reviews 33.2 (2000): 199-227. 
77. Silver, Jonathan M., Thomas W. McAllister, and David B. Arciniegas. "Depression and 
cognitive complaints following mild traumatic brain injury."American Journal of 
Psychiatry (2009). 
78. Skaper, Stephen D., ed. Neurotrophic factors: Methods and protocols. Totowa, NJ, 
USA:: Humana Press, 2012. 
79. Spencer, Jeremy PE. "Food for thought: the role of dietary flavonoids in enhancing 
human memory, learning and neuro-cognitive performance."Proceedings of the Nutrition 
Society 67.02 (2008): 238-252 
80. Smith, Douglas H., et al. "Evaluation of memory dysfunction following experimental 
brain injury using the Morris water maze." Journal of neurotrauma 8.4 (1991): 259-269. 
81. Stoica, Bogdan A., and Alan I. Faden. “Cell Death Mechanisms and Modulation in 
Traumatic Brain Injury.” Neurotherapeutics : the journal of the American Society for 
Experimental NeuroTherapeutics 7.1 (2010): 3–12. PMC. Web. 11 Jan. 2016. 
100 
82. Sun, Dong, et al. "Cell proliferation and neuronal differentiation in the dentate gyrus in 
juvenile and adult rats following traumatic brain injury." Journal of neurotrauma 22.1 
(2005): 95-105. 
83. Sun, Dong, et al. "Anatomical integration of newly generated dentate granule neurons 
following traumatic brain injury in adult rats and its association to cognitive recovery." 
Experimental neurology 204.1 (2007): 264-272. 
84. Sun, Dong, et al. "Basic fibroblast growth factor-enhanced neurogenesis contributes to 
cognitive recovery in rats following traumatic brain injury."Experimental neurology 
216.1 (2009): 56-65. 
85. Sun, Dong, et al. "The effect of epidermal growth factor in the injured brain after trauma 
in rats."Journal of neurotrauma 27.5 (2010): 923-938. 
86. Thurman, David J., et al. "Traumatic brain injury in the United States: a public health 
perspective."The Journal of head trauma rehabilitation 14.6 (1999): 602-615. 
87. Tsao, Jack W. Traumatic brain injury: A clinician's guide to diagnosis, management, and 
rehabilitation. Springer Science & Business Media, 2010. 
88. Villasana, Laura E., et al. "Functional integration of adult-born hippocampal neurons 
after traumatic brain injury." eneuro 2.5 (2015): ENEURO-0056. 
89. Wang, Xiaoting, et al. "Traumatic Brain Injury Severity Affects Neurogenesis in Adult 
Mouse Hippocampus." Journal of neurotrauma (2015). 
90. Waterhouse, Emily G., and Baoji Xu. "New insights into the role of brain-derived 
neurotrophic factor in synaptic plasticity." Molecular and Cellular Neuroscience 42.2 
(2009): 81-89. 
91. Wood, Paul, ed. Neuroinflammation: mechanisms and management. Springer Science & 
Business Media, 2002. 
92. Yoshii, Akira, and Martha Constantine Paton. "Postsynaptic BDNF TrkB signaling in 
synapse maturation, plasticity, and disease." Developmental neurobiology 70.5 (2010): 
304-322. 
93. Yu, Seongjin, et al. "Severity of controlled cortical impact traumatic brain injury in rats 
and mice dictates degree of behavioral deficits." Brain research 1287 (2009): 157-163. 
101 
94. Zhang, Zhentao, et al. "7, 8-dihydroxyflavone prevents synaptic loss and memory deficits 
in a mouse model of Alzheimer’s disease."Neuropsychopharmacology 39.3 (2014): 638-
650. 
95. Zhao, Chunmei, Wei Deng, and Fred H. Gage. "Mechanisms and functional implications 
of adult neurogenesis." Cell 132.4 (2008): 645-660. 
 
